[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1449
1. Sudakin V: Purification of the mitotic checkpoint complex (MCC) and the anaphase promoting complex/cyclosome (APC/C) from HeLa cells. Cold Spring Harb Protoc; 2010 Jun;2010(6):pdb.prot5449
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification of the mitotic checkpoint complex (MCC) and the anaphase promoting complex/cyclosome (APC/C) from HeLa cells.
  • In this protocol, active anaphase promoting complex/cyclosome (APC/C) and its inhibitor, mitotic checkpoint complex (MCC), are purified from HeLa cell extracts.
  • The MCC is further purified by an additional gel filtration step.
  • The APC/C activity and the ability of MCC to inhibit the APC/C are assayed at every stage of the purification procedure by in vitro ubiquitination assays.
  • [MeSH-major] Biochemistry / methods. Cell Cycle Proteins / isolation & purification. Mitosis. Ubiquitin-Protein Ligase Complexes / isolation & purification
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cell Extracts. Chemical Fractionation. Chromatography, Gel. Chromatography, High Pressure Liquid. Chromatography, Ion Exchange. HeLa Cells. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516187.001).
  • [ISSN] 1559-6095
  • [Journal-full-title] Cold Spring Harbor protocols
  • [ISO-abbreviation] Cold Spring Harb Protoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cell Extracts; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


2. Wilk M, Liszka Ł, Paleń P, Gabriel A, Laudański P: Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions - are they correlated? Pathol Res Pract; 2010 Apr 15;206(4):217-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions - are they correlated?
  • The data on the association between angiogenesis and mast cell density in cervical tumors and pretumoral conditions are scanty.
  • (1) to assess microvessel density and mast cell density in cervical lesions as well as in normal cervix samples and (2) to study the correlation between these variables.
  • Four study groups were distinguished: normal cervix samples, low-grade squamous intraepithelial lesions, high-grade squamous intraepithelial lesions, and invasive squamous cell carcinomas.
  • The immunohistochemistry was performed using anti-CD34, Anti-Human Mast Cell Tryptase, and Anti-Human Mast Cell Chymase antibodies.
  • The microvessels and mast cells in the corresponding areas of tissue samples were counted by three observers using a multi-headed microscope.
  • Microvessel density and density of mast cells that contain tryptase increased from normal samples through intraepithelial lesions to invasive carcinoma.
  • The density of mast cells containing chymase was significantly higher in invasive carcinomas than in normal samples.
  • In the entire study population, but not in the separated study groups, significant correlations between microvessel density and mast cell density were found.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Mast Cells / pathology. Neovascularization, Pathologic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cell Count. Cervix Uteri / pathology. Female. Humans. Immunohistochemistry. Statistics, Nonparametric


3. Shklovskaya E, Fazekas de St Groth B: Severely impaired clonal deletion of CD4+ T cells in low-dose irradiated mice: role of T cell antigen receptor and IL-7 receptor signals. J Immunol; 2006 Dec 15;177(12):8320-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severely impaired clonal deletion of CD4+ T cells in low-dose irradiated mice: role of T cell antigen receptor and IL-7 receptor signals.
  • Systemic administration of high doses of soluble Ag induces peripheral CD4+ T cell tolerance in unmanipulated hosts.
  • To test whether tolerance is modified under conditions of transient lymphopenia, we tracked the response of 5C.C7 TCR-transgenic CD4+ T cells to i.v. moth cytochrome c peptide in mice that received low-dose gamma irradiation 10 days previously.
  • This model was chosen because it does not support spontaneous lymphopenia-induced proliferation of 5C.C7 cells, allowing the study of Ag-specific responses without interference from simultaneous spontaneous proliferation.
  • Amplified TCR triggering was observed in irradiated hosts, consistent with dendritic cell activation leading to enhanced Ag presentation.
  • Failure of deletion was accompanied by persistent T cell activation and accumulation of Th1 effector cells.
  • Cells with memory and naive phenotypes were both represented within persistent clones, but no Th1 function could be demonstrated within the long-term memory population.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Clonal Deletion. Receptors, Antigen, T-Cell / immunology. Receptors, Interleukin-7 / metabolism. Signal Transduction / immunology
  • [MeSH-minor] Animals. Antigen Presentation. Autoimmune Diseases / etiology. Clone Cells / cytology. Clone Cells / immunology. Immune Tolerance. Lymphocyte Activation. Lymphopenia / immunology. Mice. Mice, Transgenic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142728.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Interleukin-7
  •  go-up   go-down


Advertisement
4. Concannon R, Larcos GS, Veness M: The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol; 2010 Jan;62(1):76-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare cutaneous malignancy with high mortality.
  • Positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) has been shown to be valuable in the management of many types of cancer, and the purpose of this work was to determine its utility for patients with MCC.
  • OBJECTIVE: We sought to evaluate the impact of (18)F-FDG PET with simultaneous computed tomography (PET-CT) on the staging and management of patients with MCC.
  • METHODS: We reviewed the medical records of 18 patients with MCC who underwent 21 PET-CT scans at our institution from 2006 to 2008.
  • All proven sites of MCC greater than 5 mm were positive on PET-CT with average maximum standardized uptake values (SUV max) of 4 in primary lesions, 5.6 in nodal disease and 11.5 in distant metastases.
  • Two patients were found to have a second primary malignancy, but this did not alter management.
  • Most patients had stage II or III disease, suggesting some potential referral bias.
  • CONCLUSIONS: (18)F-FDG PET-CT had a high impact in the management of MCC patients in our series and this investigation merits further assessment.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Neoplasm Staging / methods. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082888.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Mohit M, Mosallai A, Monabbati A, Mortazavi H: Merkel cell carcinoma of the vulva. Saudi Med J; 2009 May;30(5):717-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the vulva.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Vulvar Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417978.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


6. King MM, Osswald MB: Adjuvant chemotherapy for Merkel cell carcinoma. Am J Clin Oncol; 2005 Dec;28(6):634
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for Merkel cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Chemotherapy, Adjuvant. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Extremities. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Radiotherapy, Adjuvant. Reoperation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Clin Oncol. 2004 Oct;27(5):510-5 [15596922.001]
  • (PMID = 16317279.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Cecchi R, Buralli L, De Gaudioc C: Sentinel lymphonodectomy in non-melanoma skin cancers. Chir Ital; 2006 May-Jun;58(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymphonodectomy in non-melanoma skin cancers.
  • There are various types of non-melanoma skin cancers with an increased risk of local recurrence and metastasis.
  • Metastases from non-melanoma skin cancer most frequently spread to the regional nodal basins, and the presence of nodal involvement carries a poor prognosis.
  • Whereas extensive literature has shown the major role of sentinel lymphonodectomy in the management of malignant melanoma, experience with this procedure in non-melanoma skin cancers is fairly limited.
  • We report on 10 selected patients with high-risk non-melanoma skin cancer, managed with sentinel lymphonodectomy.
  • A metastatic sentinel lymph-node was found in 1 patient with recurrent cutaneous squamous cell carcinoma and in 1 patient with Merkel cell carcinoma.
  • Previous reported data and our experience provide evidence that sentinel lymphonodectomy is a feasible and minimally invasive staging procedure also in patients with high-risk non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Carcinoma, Squamous Cell / surgery. Lymph Node Excision. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845872.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Reimer JM, Enoksson M, Samollow PB, Hellman L: Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases. Mol Immunol; 2008 Apr;45(7):2116-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended substrate specificity of opossum chymase--implications for the origin of mast cell chymases.
  • Serine proteases are major granule constituents of mast cells, neutrophils, T cells and NK cells.
  • The mast cell chymase locus e.g. comprises at least one alpha-chymase, one cathepsin G, and two granzyme genes in almost all mammalian species investigated.
  • Phylogenetic analyses place one of them clearly with the alpha-chymases, whereas the other gene is equally related to cathepsin G and the granzymes.
  • To study the function of opossum chymase, and to explore the evolutionary origin of mast cell chymases, we have analyzed the cleavage specificity of this enzyme.
  • The protease was expressed in mammalian cells and the extended substrate specificity was determined using a randomized phage-displayed nonapeptide library.
  • This is in contrast to human chymase and mouse mast cell protease-4, which prefer Phe over Tyr and Trp in this position.
  • However, in most other positions this enzyme shows amino acid preferences very similar to human chymase and mouse mast cell protease-4, i.e. aliphatic amino acids in positions P4, P3, P2 and P1', and acidic amino acids (Glu and Asp) in the P2' position.
  • The overall specificity of MC chymase thereby seems to have been conserved over almost 200 million years of mammalian evolution, indicating a strong selective pressure in maintaining this specificity and an important role for these enzymes in mast cell biology.
  • [MeSH-major] Chymases / metabolism. Mast Cells / enzymology. Opossums / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022236.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR014214
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 0 / DNA, Complementary; 0 / Recombinant Proteins; EC 3.4.21.39 / Chymases
  •  go-up   go-down


9. Kleinschmidt S, Meneses F, Nolte I, Hewicker-Trautwein M: Characterization of mast cell numbers and subtypes in biopsies from the gastrointestinal tract of dogs with lymphocytic-plasmacytic or eosinophilic gastroenterocolitis. Vet Immunol Immunopathol; 2007 Dec 15;120(3-4):80-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of mast cell numbers and subtypes in biopsies from the gastrointestinal tract of dogs with lymphocytic-plasmacytic or eosinophilic gastroenterocolitis.
  • It has been suggested but not proven that hypersensitivity type I reactions are involved in the pathogenesis of canine inflammatory bowel disease (IBD).
  • The main effector cells in type I hypersensitivity reactions are mast cells (MCs).
  • Canine MCs, as human MCs, can be subdivided into three subtypes according to their content of mast cell-specific proteases: tryptase (MCT), chymase (MCC), or tryptase and chymase bearing MCs (MCTC).
  • In this study, numbers and subsets of mast cells were investigated in biopsies from the gastrointestinal tract of dogs with histopathologically confirmed lymphocytic-plasmacytic enteritis (LPE) (n=4), lymphocytic-plasmacytic colitis (LPC) (n=1) and eosinophilic gastroenterocolitis (EGE) (n=11).
  • Paraffin sections of formalin-fixed samples from the stomach, small intestine (duodenum, jejunum, ileum) and colon were stained by using a metachromatic staining method (kresylecht-violet;.
  • KEV) and a combined enzyme histochemical and immunohistochemical technique for chymase and tryptase.
  • Additionally, immunohistochemistry with antibodies against T cells (CD3), macrophages (myeloid/histiocyte antigen) and IgA, IgG and IgM bearing cells was conducted.
  • Quantitative evaluation of mast cells and semiquantitative scoring of immunohistochemically stained cells were performed.
  • Between the two histopathologically defined groups clear differences concerning mast cell numbers were detected.
  • This reduction could be due to mast cell degranulation, a T helper cell 1 dominated reaction pattern or a "thinning out" due to increasing T cells, IgA and IgG bearing cells.
  • Dogs with EGE displayed higher variability in mast cell numbers but most of the affected large and small intestinal locations had increased numbers of MCs.
  • In these cases, T cells, IgA bearing cells and macrophages also increased.
  • Increased numbers of MCs and eosinophils seen in the intestinal mucosa of dogs with EGE could indicate the presence of a type I hypersensitivity reaction (T helper cell 2 pattern) in response to dietary antigens.
  • Changes in cell numbers occurred also in unaffected locations of dogs with LPE/LPC and EGE which showed reduced MCT,C,TC, increased KEV positive cells and partially increased leucocytes and macrophages.
  • [MeSH-major] Biopsy / veterinary. Dog Diseases / immunology. Eosinophilia / veterinary. Gastroenteritis / veterinary. Gastrointestinal Tract / immunology. Mast Cells / classification. Mast Cells / cytology
  • [MeSH-minor] Animals. Cell Count. Dogs. Female. Immunohistochemistry / veterinary. Irritable Bowel Syndrome / immunology. Irritable Bowel Syndrome / pathology. Irritable Bowel Syndrome / veterinary. Male

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • MedlinePlus Health Information. consumer health - Gastroenteritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850882.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Li N, Sun Z, Jiang F: Prediction of protein-protein binding site by using core interface residue and support vector machine. BMC Bioinformatics; 2008;9:553
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity, specificity, and MCC for the prediction of the core interface residues were 60.6%, 53.4%, and 0.243, respectively.
  • The sensitivity, specificity, and MCC of this test were 57.5%, 32.5%, and 0.168, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Struct Biol. 2002 Feb;12(1):21-7 [11839485.001]
  • [Cites] Proteins. 2007 Sep 1;68(4):813-23 [17554779.001]
  • [Cites] Proteins. 2007 Dec 1;69(4):801-8 [17803216.001]
  • [Cites] Proteins. 2007 Dec 1;69(4):743-9 [17803232.001]
  • [Cites] Proteins. 2007 Dec 1;69(4):704-18 [17918726.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D190-5 [18045787.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):637-43 [16554755.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):235-42 [10592235.001]
  • [Cites] Proteins. 2000 Jun 1;39(4):331-42 [10813815.001]
  • [Cites] J Mol Biol. 2001 Mar 16;307(1):447-63 [11243830.001]
  • [Cites] Proteins. 2001 Aug 15;44(3):336-43 [11455607.001]
  • [Cites] J Mol Biol. 2001 Aug 10;311(2):395-408 [11478868.001]
  • [Cites] J Mol Biol. 2002 Feb 8;316(1):139-54 [11829509.001]
  • [Cites] Eur J Biochem. 2002 Mar;269(5):1356-61 [11874449.001]
  • [Cites] Proteins. 2002 May 15;47(3):334-43 [11948787.001]
  • [Cites] J Mol Biol. 2003 Feb 7;326(1):255-61 [12547207.001]
  • [Cites] J Mol Biol. 2003 Feb 28;326(4):1289-302 [12589769.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):208-15 [12634794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5772-7 [12730379.001]
  • [Cites] Protein Eng Des Sel. 2004 Feb;17(2):165-73 [15047913.001]
  • [Cites] J Mol Biol. 2004 Apr 16;338(1):181-99 [15050833.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i371-8 [15262822.001]
  • [Cites] J Mol Biol. 1983 Dec 25;171(4):479-88 [6663622.001]
  • [Cites] Biopolymers. 1983 Dec;22(12):2577-637 [6667333.001]
  • [Cites] Science. 1991 Jul 12;253(5016):164-70 [1853201.001]
  • [Cites] Proteins. 1994 Nov;20(3):216-26 [7892171.001]
  • [Cites] Prog Biophys Mol Biol. 1995;63(1):31-65 [7746868.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):13-20 [8552589.001]
  • [Cites] J Mol Biol. 1996 Mar 29;257(2):342-58 [8609628.001]
  • [Cites] Protein Sci. 1997 Jan;6(1):53-64 [9007976.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):707-26 [9126848.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] J Mol Biol. 1997 Sep 12;272(1):121-32 [9299342.001]
  • [Cites] J Mol Biol. 1999 Feb 5;285(5):2177-98 [9925793.001]
  • [Cites] FEBS J. 2005 Jan;272(2):293-312 [15654870.001]
  • [Cites] Bioinformatics. 2005 Apr 15;21(8):1487-94 [15613384.001]
  • [Cites] Proteins. 2005 Aug 1;60(2):263-8 [15981258.001]
  • [Cites] Proteins. 2005 Aug 1;60(2):214-6 [15981264.001]
  • [Cites] Proteins. 2005 Oct 1;61(1):21-35 [16080151.001]
  • [Cites] Proteins. 2006 Mar 15;62(3):630-40 [16329107.001]
  • [Cites] Proteins. 2006 May 15;63(3):479-89 [16450362.001]
  • [Cites] Nucleic Acids Res. 2006;34(13):3698-707 [16893954.001]
  • [Cites] Proteins. 2006 Oct 1;65(1):111-23 [16894615.001]
  • [Cites] J Mol Biol. 2006 Sep 15;362(2):365-86 [16919296.001]
  • [Cites] Proteins. 2006 Nov 15;65(3):607-22 [16955490.001]
  • [Cites] Proteins. 2007 May 1;67(2):400-17 [17299750.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W357-62 [17526530.001]
  • [Cites] Curr Opin Struct Biol. 2002 Feb;12(1):28-35 [11839486.001]
  • (PMID = 19102736.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins
  • [Other-IDs] NLM/ PMC2627892
  •  go-up   go-down


11. Rackwitz B, Limm H, Wessels T, Ewert T, Stucki G: Practicability of segmental stabilizing exercises in the context of a group program for the secondary prevention of low back pain. An explorative pilot study. Eura Medicophys; 2007 Sep;43(3):359-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 48% and 78% of the participants with present LBP experienced a minimal, clinically important change (minimal clinical changes, [MCC]) while performing SSE.
  • No strong interrelations between the ability to correctly perform SSE and the MCC of LBP could be identified.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pain Measurement. Patient Compliance. Patient Education as Topic. Pilot Projects. Prone Position. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17828060.001).
  • [ISSN] 0014-2573
  • [Journal-full-title] Europa medicophysica
  • [ISO-abbreviation] Eura Medicophys
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


12. Strasser H, Amann K, Schrott KM, Krause FS: Solitary metastasis of a Merkel cell tumor to the urinary bladder. Anticancer Res; 2008 Mar-Apr;28(2B):1361-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastasis of a Merkel cell tumor to the urinary bladder.
  • The primary Merkel cell carcinoma, a neuroendocrine tumor, mostly appears on skin areas exposed to light.
  • Lymphogenic and hematogenic metastasizing to the urinary bladder is rare, however infiltrating tumor growth into the urinary bladder occurs more frequently.
  • In urology, the Merkel cell tumor has been detected only sporadically, while infiltration of the bladder has been described in three cases worldwide.
  • We report the case of a patient with a single metastasis of a Merkel cell tumor in the urinary bladder, after excision of the femoral primary cancer two years earlier.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Skin Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505079.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Walter JH, Patterson A, Till J, Besley GT, Fleming G, Henderson MJ: Bloodspot acylcarnitine and amino acid analysis in cord blood samples: efficacy and reference data from a large cohort study. J Inherit Metab Dis; 2009 Feb;32(1):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to test the feasibility of cord blood screening for inherited metabolic disease, a two-year cohort study of births in six obstetric units from five towns in the north of England was undertaken.
  • The purpose of the study was to determine whether early detection of metabolic disease was possible and whether early intervention would improve prognosis.
  • The following disorders were detected: medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (1 case), 3-methylcrotonyl-CoA carboxylase (MCC) deficiency (2 cases), maternal carnitine transporter defect (2 cases), maternal MCC (1 case).
  • The following disorders were diagnosed subsequently but were not detected by the cord blood screening: phenylketonuria (PKU) (1 case), maple syrup urine disease (MSUD) (2 cases), argininosuccinic aciduria (1 case), methylmalonic acidaemia (MMA) (1 case), glutaric aciduria type 2 (1 case), MCAD deficiency (2 cases), 3-hydroxy-3-methylglutaryl-CoA lyase deficiency (1 case).
  • CONCLUSIONS: Cord blood testing is of limited value in detecting inherited metabolic disease.
  • [MeSH-minor] Cohort Studies. Efficiency. False Negative Reactions. Fetal Diseases / blood. Fetal Diseases / diagnosis. Humans. Infant, Newborn. Metabolic Diseases / blood. Metabolic Diseases / diagnosis. Mothers. Neonatal Screening / methods. Neonatal Screening / standards. Reference Values. Time Factors

  • Hazardous Substances Data Bank. L-CARNITINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Inherit Metab Dis. 1995;18(4):430-4 [7494401.001]
  • [Cites] J Inherit Metab Dis. 2006 Oct;29(5):627-30 [16865412.001]
  • [Cites] J Med Genet. 1998 May;35(5):366-70 [9610798.001]
  • [Cites] Pediatrics. 2003 Jun;111(6 Pt 1):1399-406 [12777559.001]
  • [Cites] Pediatr Neurol. 1992 Sep-Oct;8(5):333-7 [1418175.001]
  • [Cites] Acta Paediatr Suppl. 1999 Dec;88(432):48-51 [10626578.001]
  • [Cites] Eur J Pediatr. 1996 Mar;155(3):205-10 [8929729.001]
  • [Cites] J Inherit Metab Dis. 1984;7 Suppl 1:13-7 [6434837.001]
  • [Cites] J Inherit Metab Dis. 2005;28(3):415-23 [15868474.001]
  • [Cites] J Inherit Metab Dis. 2005;28(3):407-14 [15868473.001]
  • [Cites] J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):383-9 [16763906.001]
  • [Cites] Arch Dis Child. 1982 Dec;57(12):918-21 [7181520.001]
  • [Cites] Lancet. 2007 Jan 6;369(9555):37-42 [17208640.001]
  • (PMID = 19191006.001).
  • [ISSN] 1573-2665
  • [Journal-full-title] Journal of inherited metabolic disease
  • [ISO-abbreviation] J. Inherit. Metab. Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acids; 0 / acylcarnitine; S7UI8SM58A / Carnitine
  •  go-up   go-down


14. Xie Z, Hu X, Chen X, Sun J, Shi Q, Jing X: Synthesis and characterization of novel biodegradable poly(carbonate ester)s with photolabile protecting groups. Biomacromolecules; 2008 Jan;9(1):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Novel biodegradable poly(carbonate ester)s with photolabile protecting groups were synthesized by ring-opening copolymerization of L-lactide (LA) with 5-methyl-5-(2-nitro-benzoxycarbonyl)-1,3-dioxan-2-one (MNC) with diethyl zinc (Et2Zn) as catalyst.
  • The poly(L-lactide-co-5-methyl-5-carboxyl-1,3-dioxan-2-one) (P(LA-co-MCC)) was obtained by UV irradiation of poly(L-lactide acid-co-5-methyl-5-(2-nitro-benzoxycarbonyl)-1,3-dioxan-2-one) (P(LA-co-MNC)) to remove the protective 2-nitrobenzyl group.
  • The free carboxyl groups on the copolymers P(LA-co-MCC) were reacted with paclitaxel, a common antitumor drug.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067260.001).
  • [ISSN] 1526-4602
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbonates; 0 / Esters
  •  go-up   go-down


15. Marcantoni A, Carabelli V, Vandael DH, Comunanza V, Carbone E: PDE type-4 inhibition increases L-type Ca(2+) currents, action potential firing, and quantal size of exocytosis in mouse chromaffin cells. Pflugers Arch; 2009 Mar;457(5):1093-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PDE type-4 inhibition increases L-type Ca(2+) currents, action potential firing, and quantal size of exocytosis in mouse chromaffin cells.
  • We studied the effects of the cAMP-hydrolyzing enzyme phosphodiesterase type-4 (PDE4) on the L-type Ca(2+) channels (LTCCs) and Ca(2+)-dependent secretion in mouse chromaffin cells (MCCs).
  • The selective PDE4 inhibitor rolipram (3 microM) had a specific potentiating action on Ca(2+) currents of MCCs (40% increase within 3 min).
  • This suggests that at rest, LTCCs in MCCs are down-regulated by the low levels of cAMP determined by PDE4 activity and that LTCCs can be up-regulated by either inhibiting PDE4 or activating beta(1)-AR.
  • PDE4 inhibition had also a marked effect on the spontaneous firing of resting MCCs and catecholamine secretion.
  • Acceleration of AP firing was also induced by the LTCC-agonist Bay K (1 microM), while nifedipine (3 microM) reduced the firing frequency, suggesting that LTCCs and intracellular cAMP play a key role in setting the pace-maker current regulating MCCs excitability.
  • Thus, rolipram acts on MCCs by up-regulating both exocytosis and AP firings.
  • [MeSH-major] Action Potentials / drug effects. Calcium Channels, L-Type / physiology. Chromaffin Cells / physiology. Exocytosis / drug effects. Phosphodiesterase 4 Inhibitors. Phosphodiesterase Inhibitors / pharmacology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):845-56 [16691439.001]
  • [Cites] J Physiol. 2007 Oct 1;584(Pt 1):149-65 [17690152.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10545-50 [8631854.001]
  • [Cites] Neuroscience. 2006 Dec 1;143(2):445-59 [16962713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5543-8 [12700358.001]
  • [Cites] Br J Pharmacol. 1991 Dec;104(4):839-46 [1725765.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22100-6 [11285265.001]
  • [Cites] Physiol Rev. 2006 Oct;86(4):1093-131 [17015485.001]
  • [Cites] FEBS Lett. 1994 Aug 8;349(3):331-7 [8050592.001]
  • [Cites] Biochem J. 2006 Oct 1;399(1):111-9 [16784416.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2005 Mar;27(2):101-18 [15834463.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Biochem Pharmacol. 1992 Dec 1;44(11):2105-10 [1335250.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):251-9 [16415865.001]
  • [Cites] Neuropeptides. 1988 Jan;11(1):17-21 [2835702.001]
  • [Cites] J Physiol. 2002 Jul 15;542(Pt 2):453-76 [12122145.001]
  • [Cites] J Physiol. 1999 Oct 15;520 Pt 2:503-12 [10523418.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2123-30 [15615842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10754-8 [1961743.001]
  • [Cites] Annu Rev Biochem. 2007;76:481-511 [17376027.001]
  • [Cites] J Neurophysiol. 1999 May;81(5):2267-78 [10322065.001]
  • [Cites] Br J Pharmacol. 1992 Jun;106(2):360-6 [1382780.001]
  • [Cites] J Appl Physiol (1985). 2001 Jan;90(1):10-6 [11133887.001]
  • [Cites] Pflugers Arch. 1998 Jun;436(1):75-82 [9560449.001]
  • [Cites] J Neurochem. 2005 Mar;92(5):1126-39 [15715663.001]
  • [Cites] J Physiol. 1992;453:97-131 [1464851.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:751-73 [11264475.001]
  • [Cites] Cell. 2000 Jul 7;102(1):89-97 [10929716.001]
  • [Cites] Neuroscience. 1983 Dec;10(4):1455-62 [6320053.001]
  • [Cites] Eur Heart J. 1997 Jan;18 Suppl A:A15-26 [9049536.001]
  • [Cites] Biophys J. 2006 Mar 1;90(5):1830-41 [16361341.001]
  • [Cites] FASEB J. 2003 Feb;17 (2):330-2 [12490549.001]
  • [Cites] J Neurosci Methods. 2000 Nov 30;103(2):151-6 [11084207.001]
  • [Cites] J Neurophysiol. 2004 Nov;92(5):2633-41 [15486420.001]
  • [Cites] Cell. 2003 Jul 11;114(1):75-86 [12859899.001]
  • [Cites] J Physiol. 2002 May 1;540(Pt 3):921-39 [11986380.001]
  • [Cites] J Neurophysiol. 1996 Aug;76(2):1195-211 [8871230.001]
  • [Cites] Nature. 1984 May 3-9;309(5963):69-71 [6201747.001]
  • [Cites] J Neurophysiol. 2005 Sep;94(3):2093-104 [15944233.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):60-3 [1538782.001]
  • [Cites] J Physiol. 2001 Apr 1;532(Pt 1):73-90 [11283226.001]
  • [Cites] Pharmacol Ther. 2003 Apr;98(1):1-34 [12667886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Nov;79(21):6712-6 [6959149.001]
  • [Cites] Biophys J. 2003 Aug;85(2):1326-37 [12885675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6735-40 [9192634.001]
  • [Cites] J Biol Chem. 1995 Feb 24;270(8):3498-505 [7876083.001]
  • [Cites] J Physiol. 2002 Jun 1;541(Pt 2):351-66 [12042344.001]
  • [Cites] Circ Res. 2002 May 17;90(9):981-7 [12016264.001]
  • [Cites] J Neurosci. 2008 Mar 26;28(13):3350-8 [18367602.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):514-20 [11502882.001]
  • [Cites] Circ Res. 2008 May 9;102(9):1091-100 [18369156.001]
  • [Cites] Eur J Neurosci. 1999 Oct;11(10):3574-84 [10564365.001]
  • [Cites] J Physiol. 1982 Oct;331:577-97 [6296371.001]
  • [Cites] J Neurosci. 2003 Oct 22;23(29):9650-63 [14573545.001]
  • [Cites] Neuron. 1996 Jun;16(6):1209-20 [8663997.001]
  • [Cites] J Neurosci. 2003 Aug 27;23(21):7917-21 [12944522.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jul 30;194(2):671-6 [8393669.001]
  • [Cites] Pflugers Arch. 2001 Sep;442(6):801-13 [11680611.001]
  • [Cites] Br J Pharmacol. 1999 May;127(1):65-74 [10369457.001]
  • [Cites] J Physiol. 2004 Jul 15;558(Pt 2):433-49 [15133061.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):73-83 [12514203.001]
  • [Cites] Cell Calcium. 2007 Oct-Nov;42(4-5):397-408 [17561252.001]
  • [Cites] Mol Neurobiol. 2004 Feb;29(1):73-96 [15034224.001]
  • [Cites] Neuron. 2004 Feb 5;41(3):417-29 [14766180.001]
  • (PMID = 18779976.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cacna1d protein, mouse; 0 / Calcium Channels, L-Type; 0 / Ethanolamines; 0 / Phosphodiesterase 4 Inhibitors; 0 / Phosphodiesterase Inhibitors; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram; TBT296U68M / 1-Methyl-3-isobutylxanthine; V5F60UPD8P / denopamine
  •  go-up   go-down


16. Peloschek P, Novotny C, Mueller-Mang C, Weber M, Sailer J, Dawid M, Czerny C, Dudczak R, Kletter K, Becherer A: Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol; 2010 Feb;73(2):317-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET.
  • OBJECTIVE: The authors report imaging findings in a series of 16 patients with MCC, a rare tumour which is often managed primarily by a dermatologist.
  • To our knowledge, no equivalent series of MCC has been described in the nuclear medicine literature.
  • MATERIAL AND METHODS: In this IRB-approved retrospective noncomparative case series 16 patients with biopsy-proven Merkel cell carcinoma were included between January 1999 and October 2007.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Fluorodeoxyglucose F18. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19108971.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Rothe JH, Denecke T, Röttgen R: [Merkel cell carcinoma: a rare tumor entity in an unusually young patient]. Rofo; 2009 Mar;181(3):270-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma: a rare tumor entity in an unusually young patient].
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Contrast Media. Disease Progression. Fatal Outcome. Fluorodeoxyglucose F18. Humans. Knee / surgery. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Surgical Flaps. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229796.001).
  • [ISSN] 1438-9010
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Bowers JW, Schlauder SM, Calder KB, Morgan MB: Acetylcholine receptor expression in Merkel cell carcinoma. Am J Dermatopathol; 2008 Aug;30(4):340-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acetylcholine receptor expression in Merkel cell carcinoma.
  • These receptors are critical for migration of neurocrest-derived cells to their corresponding tissues during development.
  • Recent reports demonstrate neurocrest-derived melanoma and numerous non-Merkel cell neuroendocrine tumors express both muscarinic and nicotinic receptors.
  • In light of the controversy surrounding the origin and pathogenesis of Merkel cell carcinoma (MCC), we investigated the immunohistochemical expression of both mAChR and nAChR in MCC.
  • Fifteen cases of primary non-metastatic cutaneous MCC archived at a large veterans' hospital and tertiary referral dermatopathology service were retrieved by computer-assisted search.
  • Fifteen cases of primary cutaneous MCC were diffusely positive for M3 and M5 mAChR staining.
  • Despite the limited number of cases, MCC appears to uniformly express M3 and M5 receptors.
  • These receptors have been linked to cell proliferation and migration which may confer a potential therapeutic target.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Receptors, Muscarinic / biosynthesis. Receptors, Nicotinic / biosynthesis. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645305.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Muscarinic; 0 / Receptors, Nicotinic
  •  go-up   go-down


19. Fukuyama R, Niculaita R, Ng KP, Obusez E, Sanchez J, Kalady M, Aung PP, Casey G, Sizemore N: Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene; 2008 Oct 9;27(46):6044-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription.
  • Mutated in colorectal cancer (MCC) was originally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP and the physiologic/pathologic roles of MCC remained poorly understood.
  • Recently, MCC promoter methylation was discovered as a frequent early event in a distinct subset of precursor lesions and colorectal cancer (CRC) associated with the serrated CRC pathway.
  • Here we provide the first evidence of the biological significance of MCC loss in CRC and the molecular pathways involved.
  • We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAF(V600E) mutation due to promoter methylation as reported previously.
  • Importantly, we find MCC interacts with beta-catenin and that reexpression of MCC in CRC cells specifically inhibits Wnt signaling, beta-catenin/T-cell factor/lymphoid-enhancer factor-dependent transcription and cellular proliferation even in the presence of oncogenic mutant APC.
  • We also show that MCC is localized in the nucleus and identify two functional nuclear localization signals.
  • Taken together, MCC is a nuclear, beta-catenin-interacting protein that can act as a potential tumor suppressor in the serrated CRC pathway by inhibiting Wnt/beta-catenin signal transduction.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Sep 20;18(38):5325-33 [10498885.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):653-60 [10980707.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):257-66 [15516972.001]
  • [Cites] Genes Dev. 2005 Apr 15;19(8):877-90 [15833914.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):582-8 [17065427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12577-82 [11050185.001]
  • [Cites] Gene. 2001 Apr 4;267(1):101-10 [11311560.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25883-8 [11337505.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):3863-9 [11733537.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):69-73 [12499439.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1379-89 [12556497.001]
  • [Cites] Sci STKE. 2003 Apr 22;2003(179):RE7 [12709532.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):97-105 [14743216.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] Science. 1991 Mar 15;251(4999):1366-70 [1848370.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1881-6 [1656365.001]
  • [Cites] J Biol Chem. 1996 Apr 26;271(17):10341-6 [8626604.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):798-802 [10391247.001]
  • [Cites] J Histochem Cytochem. 1999 Sep;47(9):1149-58 [10449536.001]
  • [Cites] Cancer Biomark. 2006;2(1-2):5-9 [17192055.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Mol Carcinog. 2007 May;46(5):402-13 [17186550.001]
  • [Cites] Hum Pathol. 2007 Nov;38(11):1696-702 [17707462.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4435-41 [17260021.001]
  • [Cites] J Pathol. 2007 Jul;212(3):260-8 [17516584.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1009-12 [10984057.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1021-31 [15592509.001]
  • (PMID = 18591935.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100748-04; United States / NCI NIH HHS / CA / R01 CA100748; United States / NCI NIH HHS / CA / CA 100748; United States / NCI NIH HHS / CA / R01 CA100748-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 137764-10-4 / MCC protein, human
  • [Other-IDs] NLM/ NIHMS56911; NLM/ PMC2574581
  •  go-up   go-down


20. Kalinova L, Majek O, Stehlik D, Krejci K, Bachleda P: Skin cancer incidence in renal transplant recipients - a single center study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Sep;154(3):257-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer incidence in renal transplant recipients - a single center study.
  • AIMS: To provide the first single-center study of a Czech renal transplant program that compares skin cancer risk estimates to the general population.
  • Three patients were excluded for skin cancer diagnosis before transplant.
  • The cohort was linked with the National Cancer Registry of the Czech Republic.
  • For non-melanoma skin cancer (NMSC), the observed number of cancers were compared to the expected numbers of NMSC based on national cancer incidence rates stratified by age.
  • RESULTS: We found a total of 127 cases of skin cancers in 55 patients.
  • 52/55 (94.5%) were patients with non-melanoma skin cancers, 2/55 (3.6%) patients had malignant melanoma, and we uncovered one case of merkel cell carcinoma of the skin (1.8%).
  • There were no cases of Kaposi's sarcoma, cutaneous lymphoma or malignant fibrous histiocytoma.
  • Thus, skin cancer was the most common malignant condition, representing 64.1% of all malignant tumours detected in study population.
  • CONCLUSION: We confirmed that skin cancer is a major complication in renal transplant recipients.
  • [MeSH-major] Kidney Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Carcinoma, Merkel Cell / epidemiology. Carcinoma, Merkel Cell / etiology. Czech Republic / epidemiology. Female. Humans. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048813.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


21. Kotagale N, Maniyar M, Somvanshi S, Umekar M, Patel CJ: Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine. Pharm Dev Technol; 2010 Jul-Aug;15(4):431-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present work deals with the formulation and evaluation of polymer-coated polysaccharide tablets of azathioprine prepared by direct compression method using different ratios of avicel (MCC), inulin and triacetin.
  • Drug release increased with the plasticizer (triacetin) concentration.
  • Increase in the concentration of inulin and citric acid above 5% w/w increases the drug release.
  • [MeSH-minor] Animals. Cellulose / analogs & derivatives. Cellulose / chemistry. Delayed-Action Preparations. Hardness. Hydrogen-Ion Concentration. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / pharmacokinetics. Polymethacrylic Acids / chemistry. Polysaccharides / chemistry. Rats. Rats, Wistar. Solubility. Tablets

  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20236031.001).
  • [ISSN] 1097-9867
  • [Journal-full-title] Pharmaceutical development and technology
  • [ISO-abbreviation] Pharm Dev Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Excipients; 0 / Immunosuppressive Agents; 0 / Polymethacrylic Acids; 0 / Polysaccharides; 0 / Tablets; 25086-15-1 / methylmethacrylate-methacrylic acid copolymer; 9004-34-6 / Cellulose; 9004-38-0 / cellulose acetate phthalate; MRK240IY2L / Azathioprine
  •  go-up   go-down


22. Kukko H, Vuola J, Suominen S, Koljonen V: Merkel cell carcinoma in a young pregnant woman. J Plast Reconstr Aesthet Surg; 2008 Dec;61(12):1530-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a young pregnant woman.
  • SUMMARY: We present a 27-year-old pregnant woman with Merkel cell carcinoma on the forehead.
  • It was only after recurrence that a diagnosis of Merkel cell carcinoma was made.
  • No evidence of recurrence or disease progression was found 24 months after surgery.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Facial Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Forehead. Humans. Pregnancy. Reconstructive Surgical Procedures / methods. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664089.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 28
  •  go-up   go-down


23. Barroeta JE, Farkas T: Merkel cell carcinoma and chronic lymphocytic leukemia (collision tumor) of the arm: a diagnosis by fine-needle aspiration biopsy. Diagn Cytopathol; 2007 May;35(5):293-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma and chronic lymphocytic leukemia (collision tumor) of the arm: a diagnosis by fine-needle aspiration biopsy.
  • Simultaneous involvement of the same anatomical site by two different primary malignant tumors is rare.
  • Cases of hematopoietic malignancies associated with breast and skin neoplasms have been described.
  • The association of chronic lymphocytic leukemia (CLL) and Merkel cell carcinoma (MCC) has been established, although the cause for this association is still unclear.
  • There are reports of MCC metastatic to lymph nodes involved by CLL.
  • We report the case of a 57-year-old man with history of CLL with concurrent involvement of the arm by CLL and MCC diagnosed on fine-needle aspiration biopsy (FNA).
  • To our knowledge, this is the first reported case of such tumors colliding in a nonlymphoid site, diagnosed by FNA in the English literature.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Merkel Cell / secondary. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Arm. Axilla. Biomarkers, Tumor / analysis. Humans. Keratin-20 / analysis. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Mucin-1 / analysis. Phosphopyruvate Hydratase / analysis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427219.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucin-1; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


24. Joachims Z, Feinmesser R, Purim O, Halpern M, Brenner B, Fenig E, Roizman P, Sulkes J, Feinmesser M: Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):442-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in primary and metastatic Merkel cell carcinoma.
  • Cyclooxygenase-2 (COX-2) is involved in the development and progression of many tumors, and its inhibition has been shown to block tumor growth.
  • This study examined COX-2 expression in primary and metastatic Merkel cell carcinoma (MCC).
  • Formalin-fixed paraffin-embedded tissues from 26 primary MCCs and 7 lymph node metastases were stained immunohistochemically with a monoclonal antibody directed against COX-2, and the percentage and intensity of staining were analyzed semiquantitatively.
  • Immunopositivity for COX-2 was found in 20 primary tumors (77%), and was diffuse in 16 of them (80%).
  • Staining intensity was strong in 5 tumors (19%), moderate in 6 (23%), and weak in 9 (35%).
  • This study confirms that most MCCs express COX-2 and shows that COX-2 expression is related to one parameter of aggressive behavior--a high mitotic rate--but not to any others.
  • The possibility of treating MCC with COX-2 inhibitors should be considered.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594470.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


25. Li Q, Jørgensen FS, Oprea T, Brunak S, Taboureau O: hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol Pharm; 2008 Jan-Feb;5(1):117-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human Ether-a-go-go Related Gene (hERG) potassium channel is one of the major critical factors associated with QT interval prolongation and development of arrhythmia called Torsades de Pointes (TdP).
  • The development of in silico tools to filter out potential hERG channel inhibitors in early stages of the drug discovery process is of considerable interest.
  • Our models were applied at different thresholds from 1 to 40 microm and achieved an overall accuracy up to 94% with a Matthews coefficient correlation (MCC) of 0.86 ( F-measure of 0.90 for blockers and 0.95 for nonblockers).
  • The model at a 40 microm threshold showed the best performance and was validated internally (MCC of 0.40 and F-measure of 0.57 for blockers and 0.81 for nonblockers, using a leave-one-out cross-validation).
  • Even if there is still some limitation in the assessment of hERG blockers, the performance of our model shows an improvement between 10% and 20% in the prediction of blockers compared to other methods, which can be useful in the filtering of potential hERG channel inhibitors.
  • [MeSH-major] Ether-A-Go-Go Potassium Channels / antagonists & inhibitors. Models, Molecular. Models, Theoretical
  • [MeSH-minor] Computer Simulation. Humans. Potassium Channel Blockers / pharmacology. Quantitative Structure-Activity Relationship. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197627.001).
  • [ISSN] 1543-8384
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / U54 MH074425-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ether-A-Go-Go Potassium Channels; 0 / Potassium Channel Blockers
  •  go-up   go-down


26. King EM, van der Sar SJ, Hardwick KG: Mad3 KEN boxes mediate both Cdc20 and Mad3 turnover, and are critical for the spindle checkpoint. PLoS One; 2007 Apr 04;2(4):e342
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mitotic checkpoint complex (MCC, consisting of Mad3p, Mad2p, Bub3p and Cdc20p in budding yeast) is a potent APC/C inhibitor.
  • Mutation of KEN30 abolished MCC formation and stabilised Cdc20p in mitosis.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):748-53 [12855955.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):87-100 [12887895.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1278-85 [14576056.001]
  • [Cites] J Cell Sci. 2004 Apr 1;117(Pt 9):1757-71 [15075237.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):942-52 [15182667.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):953-64 [15182668.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1439-51 [15198982.001]
  • [Cites] Chromosome Res. 2004;12(6):599-616 [15289666.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):739-51 [15340381.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] Nature. 1991 Jan 10;349(6305):132-8 [1846030.001]
  • [Cites] J Cell Biol. 1995 Nov;131(3):709-20 [7593191.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1609-20 [8994825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7965-70 [9223296.001]
  • [Cites] Science. 1997 Oct 17;278(5337):460-3 [9334304.001]
  • [Cites] Science. 1998 Feb 13;279(5353):1041-4 [9461437.001]
  • [Cites] Science. 1998 Feb 13;279(5353):1045-7 [9461438.001]
  • [Cites] EMBO J. 1998 Mar 2;17(5):1336-49 [9482731.001]
  • [Cites] Curr Biol. 1998 Jun 18;8(13):750-60 [9651679.001]
  • [Cites] J Mol Biol. 2004 Dec 3;344(4):885-92 [15544799.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1567-72 [15558047.001]
  • [Cites] Nat Cell Biol. 2005 Jan;7(1):93-8 [15592459.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):214-25 [15694304.001]
  • [Cites] Cell. 2005 Mar 25;120(6):739-46 [15797376.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13944-51 [15644329.001]
  • [Cites] Eukaryot Cell. 2005 May;4(5):867-78 [15879521.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3639-52 [16046481.001]
  • [Cites] Biophys J. 2005 Oct;89(4):2640-9 [16040755.001]
  • [Cites] EMBO J. 2005 Nov 2;24(21):3690-9 [16222337.001]
  • [Cites] Curr Biol. 2006 Apr 18;16(8):755-66 [16631582.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):153-7 [16636141.001]
  • [Cites] Exp Cell Res. 2006 Jun 10;312(10):1831-42 [16600213.001]
  • [Cites] Science. 2006 Aug 4;313(5787):680-4 [16825537.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):644-56 [16896351.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2410-20 [16921029.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):9-23 [17189715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1201-6 [17227844.001]
  • [Cites] J Cell Biol. 2000 Mar 6;148(5):871-82 [10704439.001]
  • [Cites] Genes Dev. 2000 Mar 15;14(6):655-65 [10733526.001]
  • [Cites] Cell. 2000 Jun 23;101(7):763-75 [10892747.001]
  • [Cites] Nat Rev Genet. 2001 Apr;2(4):280-91 [11283700.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):925-36 [11535616.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2396-407 [11562349.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5165-75 [11566880.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):227-37 [11702782.001]
  • [Cites] Mol Biol Cell. 2002 Mar;13(3):755-66 [11907259.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2728-42 [11909965.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2496-506 [12006501.001]
  • [Cites] Science. 2002 Jul 26;297(5581):559-65 [12142526.001]
  • [Cites] EMBO J. 2002 Sep 2;21(17):4500-10 [12198152.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Oct;3(10):731-41 [12360190.001]
  • [Cites] Cell. 2003 Feb 21;112(4):407-21 [12600307.001]
  • [Cites] Nature. 2003 Jun 26;423(6943):1009-13 [12827207.001]
  • [Cites] Cell. 2003 Jul 11;114(1):87-98 [12859900.001]
  • [Cites] Mol Cell. 2004 Jan 16;13(1):137-47 [14731401.001]
  • (PMID = 17406666.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDC20 protein, S cerevisiae; 0 / Cdc20 Proteins; 0 / Cell Cycle Proteins; 0 / MAD3 protein, S cerevisiae; 0 / Nuclear Proteins; 0 / Saccharomyces cerevisiae Proteins
  • [Other-IDs] NLM/ PMC1829190
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


27. Suzuki T, Yasuda K, Yamanishi T, Kitahara S, Nakai H, Suda S, Ohkawa H: Randomized, double-blind, sham-controlled evaluation of the effect of functional continuous magnetic stimulation in patients with urgency incontinence. Neurourol Urodyn; 2007;26(6):767-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At 10 weeks, the number of leaks/week, the total score of the International Consultation on Incontinence-Questionnaire: Short Form (ICIQ-SF), and maximum cystometric capacity (MCC) were significantly improved as compared with the initial levels (P < 0.001, P < 0.001, and P = 0.003, respectively) in the former group, but not in the latter group.
  • Four (20.0%) patients were cured in the A-S group, while no patient was cured in the S-A group.
  • At the end of the A-S schedule (24 weeks of study), the effect of the active treatment was still maintained at a significantly improved level, as compared with the initial level.
  • MCC significantly increased from its initial level (P = 0.030).
  • CONCLUSION: Magnetic stimulation was effective on urgency incontinence in comparison to sham stimulation in this small patient group.

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17397061.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


28. Poulsen MG, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, Keller J, Tripcony L: Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys; 2006 Jan 1;64(1):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?
  • PATIENTS AND METHODS: Patients were included in the analysis if they had disease localized to the primary site and nodes, and they were required to have at least one of the following high-risk features: recurrence after initial therapy, involved nodes, primary size greater than 1 cm, or gross residual disease after surgery.
  • Radiation was delivered to the primary site and nodes to a dose of 50 Gy in 25 fractions over 5 weeks, and synchronous carboplatin (AUC 4.5) and etoposide, 80 mg/m(2) i.v. on Days 1 to 3, were given in Weeks 1, 4, 7, and 10.
  • Patients with occult cutaneous disease were not included for the purpose of this analysis.
  • Overall survival, disease-specific survival, locoregional control, and distant control were used as endpoints for the study.
  • RESULTS: Of the 102 patients who had high-risk Stage I and II disease, 40 were treated with chemotherapy (TROG 96:07) and 62 were treated without chemotherapy (historic control subjects).
  • When Cox's proportional hazards modeling was applied, the only significant factors for overall survival were recurrent disease, age, and the presence of residual disease.
  • For disease-specific survival, recurrent disease was the only significant factor.
  • Primary site on the lower limb had an adverse effect on locoregional control.
  • For distant control, the only significant factor was residual disease.
  • A study of this size is inadequately powered to detect small improvements in survival, and a larger randomized study remains the only way to truly confirm whether chemotherapy improves the results in high-risk MCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / mortality. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Epidemiologic Methods. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Prognosis. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125873.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


29. Gallwitz M, Enoksson M, Hellman L: Expression profile of novel members of the rat mast cell protease (rMCP)-2 and (rMCP)-8 families, and functional analyses of mouse mast cell protease (mMCP)-8. Immunogenetics; 2007 May;59(5):391-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of novel members of the rat mast cell protease (rMCP)-2 and (rMCP)-8 families, and functional analyses of mouse mast cell protease (mMCP)-8.
  • Four hematopoietic serine proteases are common to the mast cell chymase locus of all analyzed mammals: alpha-chymase, cathepsin G, granzyme B, and granzyme C/H.
  • Apart from these common genes, the mouse and rat loci hold additional granzyme-, beta-chymase-, and Mcpt8-like genes.
  • To better understand the functional consequences of these additional enzymes and to be able to compare human and rodent immune functions, we have analyzed the expression of novel beta-chymase- and Mcpt8-like genes in the rat.
  • Four novel genes, i.e., Mcpt2-rs2a, Mcpt2-rs2c, Mcpt8-rs1, and Mcpt8-rs4 were transcribed in tissues holding mucosal mast cells (MMC), where also the classical MMC protease Mcpt2 was expressed.
  • We also found transcripts of rat vascular chymase (rVch) in some of these tissues.
  • RVch is a beta-chymase that converts angiotensin I, like the human chymase.
  • Rat MMC may therefore have similar angiotensin-converting properties as chymase-positive human mast cells, although these are mostly regarded the counterpart of rat connective tissue mast cells.
  • The human mast cells that are considered the counterpart of rat MMC express, however, only tryptase, whereas rat MMC express various proteases, but no tryptase.
  • [MeSH-major] Chymases / genetics. Tryptases / chemistry. Tryptases / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1984 Nov;83(5):336-9 [6092480.001]
  • [Cites] Biochim Biophys Acta. 1998 Jul 28;1386(1):189-98 [9675278.001]
  • [Cites] Acta Pathol Microbiol Scand. 1966;66(3):303-12 [4162018.001]
  • [Cites] J Biol Chem. 1982 Aug 10;257(15):8619-22 [6807977.001]
  • [Cites] Mol Cell. 2003 Aug;12(2):343-54 [14536074.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1871-81 [7500033.001]
  • [Cites] Biochem Biophys Res Commun. 1967 Apr 20;27(2):157-62 [6035483.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3730-7 [9842915.001]
  • [Cites] Gut. 1995 Aug;37(2):235-41 [7557574.001]
  • [Cites] Nat Struct Biol. 2003 Jul;10(7):535-40 [12819770.001]
  • [Cites] Biochem J. 1995 Oct 15;311 ( Pt 2):675-80 [7487912.001]
  • [Cites] J Exp Med. 1959 Sep 1;110:451-60 [13798801.001]
  • [Cites] Proteins. 2000 Oct 1;41(1):8-16 [10944388.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):13-29 [8996238.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 14;1480(1-2):245-57 [10899625.001]
  • [Cites] Eur J Immunol. 2005 Jan;35(1):261-72 [15593300.001]
  • [Cites] Eur J Biochem. 2002 Dec;269(23):5921-30 [12444981.001]
  • [Cites] J Recept Signal Transduct Res. 2005;25(1):35-44 [15960393.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):98-103 [1985927.001]
  • [Cites] Biol Chem. 2000 Dec;381(12):1203-14 [11209755.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18134-40 [8027075.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1061-5 [2416825.001]
  • [Cites] Eur J Pharmacol. 2006 May 24;538(1-3):175-81 [16690053.001]
  • [Cites] J Clin Invest. 2001 Mar;107(6):703-15 [11254670.001]
  • [Cites] Biochemistry. 1989 Mar 7;28(5):1951-63 [2655701.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18579-85 [11896050.001]
  • [Cites] Allergy Proc. 1994 Nov-Dec;15(6):303-8 [7721078.001]
  • [Cites] Nat Struct Biol. 1994 Jun;1(6):364-7 [7664048.001]
  • [Cites] Eur J Immunol. 2000 Sep;30(9):2660-8 [11009100.001]
  • [Cites] FEBS Lett. 1997 Jul 21;412(1):86-90 [9257695.001]
  • [Cites] Genomics. 1993 Mar;15(3):614-20 [8468056.001]
  • [Cites] Eur J Immunol. 2000 Dec;30(12):3396-402 [11093157.001]
  • [Cites] J Leukoc Biol. 2000 Apr;67(4):585-9 [10770293.001]
  • [Cites] Clin Exp Allergy. 2003 Jul;33(7):1005-12 [12859460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9017-21 [9256427.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):306-11 [9521329.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jan 6;242(1):158-63 [9439628.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Jun;82(11):3871-5 [3923482.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1519-27 [7706457.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39625-31 [12900423.001]
  • [Cites] J Exp Med. 1991 Oct 1;174(4):821-5 [1919436.001]
  • [Cites] Science. 1996 Jan 26;271(5248):502-5 [8560264.001]
  • [Cites] Protein Sci. 1995 Mar;4(3):337-60 [7795518.001]
  • [Cites] Proteins. 1990;7(4):317-34 [2381905.001]
  • [Cites] Immunogenetics. 2006 Aug;58(8):655-69 [16807745.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1033-40 [15313398.001]
  • [Cites] Eur J Pharmacol. 1998 Jul 3;352(1):91-8 [9718272.001]
  • [Cites] Genome Res. 2004 Apr;14(4):609-22 [15060002.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):128-32 [8278352.001]
  • [Cites] FASEB J. 2002 Jun;16(8):875-7 [11967231.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):762-5 [10966646.001]
  • [Cites] Immunology. 1986 May;58(1):101-4 [3519440.001]
  • [Cites] Biochemistry. 2000 Oct 24;39(42):13068-77 [11041873.001]
  • [Cites] Nat Struct Biol. 2003 Jul;10(7):527-34 [12819769.001]
  • [Cites] Immunogenetics. 2004 Aug;56(5):343-54 [15316687.001]
  • [Cites] Immunogenetics. 2003 May;55(2):109-15 [12712264.001]
  • [Cites] Clin Chim Acta. 2004 Sep;347(1-2):223-5 [15313162.001]
  • [Cites] Eur J Immunol. 1991 Jul;21(7):1611-21 [2060576.001]
  • [Cites] Biochemistry. 1987 Nov 3;26(22):6988-94 [3122823.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27364-73 [9765264.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 21;302(4):773-7 [12646236.001]
  • [Cites] Immunogenetics. 2006 Aug;58(8):641-54 [16807746.001]
  • [Cites] Br J Pharmacol. 1998 Dec;125(7):1491-500 [9884078.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):11372-9 [8098710.001]
  • [Cites] FEBS Lett. 2002 Feb 13;512(1-3):133-8 [11852067.001]
  • [Cites] Biochemistry. 1988 Oct 18;27(21):8097-105 [3233198.001]
  • [Cites] Chem Biol. 2001 Apr;8(4):357-68 [11325591.001]
  • [Cites] Eur J Biochem. 1999 Mar;260(3):571-95 [10102985.001]
  • [Cites] Immunology. 1987 Dec;62(4):629-34 [3323034.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4689-96 [7876240.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):75-89 [10708850.001]
  • [Cites] J Immunol. 1987 Apr 15;138(8):2611-5 [3549903.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nat Rev Immunol. 2003 May;3(5):361-70 [12766758.001]
  • [Cites] Biol Chem. 2006 Mar;387(3):243-9 [16542144.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5377-84 [3549719.001]
  • [Cites] Eur J Immunol. 1998 Mar;28(3):1022-33 [9541598.001]
  • [Cites] Immunogenetics. 1994;40(6):397-414 [7959952.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3381-5 [12824332.001]
  • [Cites] Pharmacol Ther. 2006 Dec;112(3):668-76 [16837049.001]
  • (PMID = 17342483.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 3.4.21.- / chymase 2; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Mcpt8 protein, mouse; EC 3.4.21.59 / Mcpt8 protein, rat; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


30. Kantola K, Sadeghi M, Lahtinen A, Koskenvuo M, Aaltonen LM, Möttönen M, Rahiala J, Saarinen-Pihkala U, Riikonen P, Jartti T, Ruuskanen O, Söderlund-Venermo M, Hedman K: Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory tract samples: implications for respiratory transmission and latency. J Clin Virol; 2009 Aug;45(4):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell polyomavirus DNA in tumor-free tonsillar tissues and upper respiratory tract samples: implications for respiratory transmission and latency.
  • BACKGROUND: Merkel cell polyomavirus (MCPyV) was discovered recently.
  • It is considered a potential causative agent of Merkel cell carcinoma, a life-threatening skin cancer.
  • [MeSH-major] Adenoids / virology. Carrier State / epidemiology. DNA, Viral / isolation & purification. Merkel Cells / virology. Polyomavirus / isolation & purification. Polyomavirus Infections / epidemiology. Respiratory System / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Feces / virology. Female. Humans. Infant. Male. Middle Aged. Prevalence. Serum / virology. Young Adult

  • MedlinePlus Health Information. consumer health - Adenoids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464943.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


31. Verheyen P, Steffens KJ, Kleinebudde P: Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties. Drug Dev Ind Pharm; 2009 Nov;35(11):1325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Microcrystalline cellulose (MCC) is the most important pelletization aid in extrusion/spheronization.
  • For comparison, pellets with MCC as extrusion aid were also produced.
  • RESULTS: Only crospovidone types exhibiting small particle sizes are suitable as pelletization aid.
  • The most distinguished differences between pellets based on crospovidone and MCC are the disintegration and drug release behavior.
  • The pellets containing binary mixtures of the low-soluble APIs and crospovidone resulted in fast release in contrast to the pellets with MCC as pelletization aid, which exhibited a slow release.

  • Hazardous Substances Data Bank. Water .
  • Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832632.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Drug Implants; 0 / Excipients; 0 / microcrystalline cellulose; 059QF0KO0R / Water; 9003-39-8 / Povidone; 9004-34-6 / Cellulose
  •  go-up   go-down


32. Shimizu T: Participation of Runx2 in mandibular condylar cartilage development. Eur J Med Res; 2006 Nov 30;11(11):455-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Participation of Runx2 in mandibular condylar cartilage development.
  • OBJECTIVE: The purpose of this study was to investigate the expression pattern of Runx2 in mandibular condylar cartilage, a type of secondary cartilage.
  • METHODS: Mandibular condyle of ddY mice were fixed from embryonic day 14 (E14) through just after birth (equivalent to E19).
  • Samples were cut into 4 micro m serial sections through the central area of the mandibular condyle at the sagittal plane.
  • RESULTS: There are no developmental features of mandibular condyle.
  • At the distal upper portion of developmental mandibular bone, mesenchymal cell proliferation and condensation without metacholomatic reaction to Toluidine blue (TB) were seen at E14.
  • At E15, mandibular condylar cartilage was clearly evident, as TB metacholomasia.
  • In IHC specimens at E14, expression of Runx2 peptide was observed in the nuclei and the cytoplasms cells of coagulating mesenchymal cells, both in the cytoplasm and nucleus.
  • After E17, Runx2 appeared in the cells of the condylar cartilage sheath.
  • CONCLUSION: These IHC and ISH results suggest that Runx2 plays an essential role for mandibular condylar cartilage development, especially that Runx2 is essential for the onset of secondary cartilage differentiation.
  • [MeSH-major] Cartilage / metabolism. Core Binding Factor Alpha 1 Subunit / metabolism. Gene Expression Regulation, Developmental. Mandibular Condyle / metabolism
  • [MeSH-minor] Animals. Cells, Cultured. Chondrocytes / metabolism. Collagen Type II / metabolism. Female. In Situ Hybridization. Mice. Osteopontin / metabolism. Pregnancy. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17182356.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Collagen Type II; 0 / Core Binding Factor Alpha 1 Subunit; 0 / RNA Probes; 0 / RNA, Messenger; 0 / Runx2 protein, mouse; 106441-73-0 / Osteopontin
  •  go-up   go-down


33. Takamura H, Yamashita H: Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol; 2005 Sep-Oct;49(5):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries.
  • PURPOSE: To report the clinical and histopathological features of malignant eyelid tumor cases treated in our clinic.
  • We also compared the differences in the frequency of malignant eyelid tumor in various regions of Japan and worldwide.
  • METHODS: Retrospectively, we studied the records of the 38 cases of malignant eyelid tumor treated in Yamagata University Hospital over the last 17 years.
  • RESULTS: Data from our clinic: Among the total of 38 cases, 15 cases (39.5%) were diagnosed as basal cell carcinoma, 11 cases (28.9%) as sebaceous gland carcinoma, and 4 cases (10.5%) as squamous cell carcinoma.
  • In addition, three cases were malignant melanoma, two adenocarcinoma, one Merkel cell carcinoma, one malignant peripheral nerve sheath tumor, and one malignant lymphoma.
  • Most of the cases were treated by complete resection of the tumors and eyelid reconstruction.
  • The prognosis of the cases with basal cell carcinoma and squamous cell carcinoma was good, and that of the other tumors was relatively poor.
  • During the same period, in Caucasians, basal cell carcinoma constituted about 80%-90% of the malignant eyelid tumors, whereas in Japan and Asian countries, basal cell carcinoma, sebaceous gland carcinoma, and squamous cell carcinoma each constituted about 20%-40%.
  • CONCLUSIONS: A racial difference in the incidence of basal cell carcinoma, sebaceous gland carcinoma, and squamous cell carcinoma can be considered in making a diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2004 Feb;18(2):135-8 [14762403.001]
  • [Cites] Br J Ophthalmol. 1999 May;83(5):595-7 [10216061.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1986 Mar;86(3):323-4, 329-33 [3802345.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):108-9 [8540844.001]
  • [Cites] Korean J Ophthalmol. 1988 Jun;2(1):27-31 [3071636.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121 [11713084.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):746-50 [10201597.001]
  • [Cites] Cancer. 1979 Jul;44(1):293-303 [455254.001]
  • [Cites] Br J Ophthalmol. 1968 Jan;52(1):43-53 [5710508.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):23-61 [7061198.001]
  • [Cites] Oftalmologia. 1996 Oct-Dec;40(4):361-7 [8962866.001]
  • [Cites] Jpn J Ophthalmol. 2000 May;44(3):320 [10913665.001]
  • [Cites] Arch Ophthalmol. 1963 Jun;69:693-7 [13927762.001]
  • [Cites] J Indian Med Assoc. 1996 Nov;94(11):405-9, 416, 418 [9141864.001]
  • [Cites] Arch De Vecchi Anat Patol. 1977 Dec;62(2-3):327-30 [756225.001]
  • [Cites] Jpn J Ophthalmol. 1983;27(1):175-84 [6855011.001]
  • [Cites] J Maxillofac Surg. 1977 Jun;5(2):93-107 [267708.001]
  • [Cites] Ophthalmologica. 1995;209(5):280-3 [8570154.001]
  • [Cites] Aust J Ophthalmol. 1984 May;12(2):121-7 [6487181.001]
  • (PMID = 16187033.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Turk T, Orlic ZC, Smoljan I, Nacinovic A, Bekafigo IS, Radic J, Zamolo G: Spontaneous regression of Merkel cell carcinoma in a patient with chronic lymphocytic leukemia: a case report. J Med Case Rep; 2009;3:7270
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of Merkel cell carcinoma in a patient with chronic lymphocytic leukemia: a case report.
  • INTRODUCTION: Merkel cell carcinoma is a rare and aggressive primary cutaneous neuroendocrine malignant tumor.
  • The tumor has a high rate of local recurrence after surgical removal.
  • Spontaneous regression appears to be relatively common in this rare type of tumor.
  • CASE PRESENTATION: We describe the clinical course, cytological and histological findings of a Merkel cell carcinoma in a 70-year-old Caucasian woman, simultaneously diagnosed with chronic lymphatic leukemia.
  • The tumor showed clinical regression after fine needle aspiration.
  • At primary presentation, the tumor had no apparent leukocyte infiltration, but was completely cleared by T-cell mediated immunity within 3 weeks after fine needle aspiration.
  • CONCLUSION: Fine needle aspiration may have acted as a mechanical trigger involved in the activation of cell-mediated immunity, leading to the clinical and histological regression of the tumor.
  • To the best of our knowledge, this is the first case report of spontaneous regression of Merkel cell carcinoma in a patient with a co-malignancy, that is to say, chronic lymphocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1991 Feb;78(2):138-42 [2015460.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):965-9 [15153905.001]
  • [Cites] Leuk Lymphoma. 1996 Feb;20(5-6):509-11 [8833412.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 1997 Jan-Jun;1(1-3):11-6 [9444793.001]
  • [Cites] Dermatol Surg. 1999 Jan;25(1):23-5 [9935088.001]
  • [Cites] Br J Dermatol. 2000 Mar;142(3):525-8 [10735964.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Br J Dermatol. 2000 Jun;142(6):1184-9 [10848744.001]
  • [Cites] Br J Dermatol. 2001 Jan;144(1):216-7 [11167728.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1358-62 [11283937.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 May;114(5):376-80 [15966524.001]
  • [Cites] BMC Cancer. 2005;5:106 [16111484.001]
  • [Cites] World J Surg Oncol. 2006;4:7 [16466578.001]
  • [Cites] Dermatol Surg. 2008 Jun;34(6):815-22 [18363731.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 Jan;16(1):82-3 [11952300.001]
  • [Cites] Am J Clin Oncol. 2003 Dec;26(6):531-4 [14663367.001]
  • [Cites] J Surg Oncol. 1981;17(3):201-9 [6166811.001]
  • (PMID = 19830161.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2726515
  •  go-up   go-down


35. Chuayjuljit S, Su-uthai S, Charuchinda S: Poly(vinyl chloride) film filled with microcrystalline cellulose prepared from cotton fabric waste: properties and biodegradability study. Waste Manag Res; 2010 Feb;28(2):109-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hydrolysis of cotton fabric waste to produce microcrystalline cellulose (MCC) was carried out using 2.5 N hydrochloric acid at 100 degrees C for 30 min.
  • Characterization of the structure, morphology, particle size as well as the thermal decomposition of the obtained MCC were studied using X-ray diffractometer, scanning electron microscope and laser light scattering particle size analyzer and thermogravimetric analyzer, respectively.
  • These results indicated that the obtained MCC had a fibrous structure of a 40 microm average particle size and possessed a form of highly native crystalline cellulose I.
  • The poly(vinyl chloride) (PVC) films in this work were produced by first blending the produced MCC with PVC resin in amounts of 5-30 parts per hundred of resin.
  • It was found that the tensile strength and Young's modulus of the blends increased with increasing amounts of MCC.
  • Similarly, moisture absorption and biodegradability of the films were also increased as the amount of MCC increased.
  • The results implied that MCC behaved not only as a reinforcing filler but also as a biodegradability promoter of PVC films.

  • Hazardous Substances Data Bank. POLYVINYL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710122.001).
  • [ISSN] 1096-3669
  • [Journal-full-title] Waste management & research : the journal of the International Solid Wastes and Public Cleansing Association, ISWA
  • [ISO-abbreviation] Waste Manag Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Industrial Waste; 0 / microcrystalline cellulose; 9002-86-2 / Polyvinyl Chloride; 9004-34-6 / Cellulose
  •  go-up   go-down


36. Oppert C, Klingeman WE, Willis JD, Oppert B, Jurat-Fuentes JL: Prospecting for cellulolytic activity in insect digestive fluids. Comp Biochem Physiol B Biochem Mol Biol; 2010 Feb;155(2):145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enzymatic activity was determined for two different substrates, carboxymethyl cellulose (CMC) and microcrystalline cellulose (MCC), approximating endo-beta-1,4-glucanase and complete cellulolytic activity, respectively.
  • Highest CMC gut fluid activities were found in Dictyoptera, Coleoptera, Isoptera, and Orthoptera, while highest MCC gut fluid activities were found in Coleoptera, Hymenoptera, Lepidoptera, and Orthoptera.
  • In most cases, gut fluid activities were greater with CMC compared to MCC substrate, except in Diptera, Hymenoptera, and Lepidoptera.
  • In contrast, cellulolytic activity levels in most head fluids were greater on the MCC substrate.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895899.001).
  • [ISSN] 1879-1107
  • [Journal-full-title] Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology
  • [ISO-abbreviation] Comp. Biochem. Physiol. B, Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / microcrystalline cellulose; 9004-32-4 / Carboxymethylcellulose Sodium; 9004-34-6 / Cellulose; EC 3.2.1.4 / Cellulase
  •  go-up   go-down


37. Szmit S, Jank M, Maciejewski H, Grabowski M, Glowczynska R, Majewska A, Filipiak KJ, Motyl T, Opolski G: Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure. J Appl Genet; 2010;51(3):353-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure.
  • Functional analysis of up- and down-regulated genes might reveal whether peripheral blood cells may be considered as a material of diagnostic or prognostic value in patients with end-stage heart failure (HF).
  • The aim of the present study was to compare the transcriptomic profile of peripheral blood nuclear cells from 6 male patients with ischaemic end-stage HF with those of 6 male patients with asymptomatic cardiac dysfunction.
  • The expression of genes in peripheral blood nuclear cells in both groups of patients was measured using whole-genome oligonucleotide microarrays utilizing 35 035 oligonucleotide probes.
  • We also identified up-regulated genes that have been correlated with HF severity (CXCL16) and genes involved in the regulation of expression of platelet activation factor receptor (PTAFR, RBPSUH, MCC, and PSMA7).
  • In conclusion, the identification of genes that are differentially expressed in peripheral blood nuclear cells of patients with HF supports the suggestion that this diagnostic approach may be useful in searching for the molecular predisposition for development of severe refractory HF in patients with post-infarction asymptomatic abnormalities and remodelling of the left ventricle.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Jun;160(6):2035-43 [12057908.001]
  • [Cites] J Am Coll Cardiol. 2006 Dec 5;48(11):2178-85 [17161242.001]
  • [Cites] Circulation. 2000 Sep 5;102(10):1126-31 [10973841.001]
  • [Cites] Genomics. 2009 Jul;94(1):20-31 [19332114.001]
  • [Cites] Eur J Heart Fail. 2001 Jun;3(3):315-22 [11378002.001]
  • [Cites] Circulation. 2003 Aug 26;108(8):977-82 [12912813.001]
  • [Cites] Lancet. 1997 Sep 20;350(9081):829-33 [9310600.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Aug;136(2):360-369.e1 [18692642.001]
  • [Cites] Cardiovasc Res. 2003 Aug 1;59(2):400-11 [12909323.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):334-41 [12520017.001]
  • [Cites] Mol Hum Reprod. 2004 Apr;10(4):229-35 [14996996.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Am Coll Cardiol. 2005 Jul 19;46(2):284-90 [16022956.001]
  • [Cites] Physiol Genomics. 2005 May 11;21(3):299-307 [15769906.001]
  • [Cites] Eur Heart J. 2001 Feb;22(3):228-36 [11161934.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1261-70 [18799560.001]
  • [Cites] Physiol Genomics. 2008 Jun 12;34(1):88-94 [18430805.001]
  • [Cites] Eur Heart J. 2004 Feb;25(4):300-7 [14984918.001]
  • [Cites] J Am Coll Cardiol. 2005 Sep 20;46(6):963-6 [16168276.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1383-90 [15942582.001]
  • [Cites] Circ J. 2009 Sep;73(9):1568-76 [19638707.001]
  • [Cites] Physiol Genomics. 2005 Apr 14;21(2):131-43 [15831843.001]
  • [Cites] Circulation. 2004 Nov 30;110(22):3444-51 [15557369.001]
  • [Cites] Physiol Genomics. 2006 Nov 27;27(3):309-17 [16882888.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6044-55 [18591935.001]
  • [Cites] Circulation. 2005 Sep 20;112(12):e154-235 [16160202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11387-92 [12177426.001]
  • [Cites] Circ Res. 2008 Mar 28;102(6):661-8 [18239137.001]
  • [Cites] Circ Heart Fail. 2009 Nov;2(6):624-32 [19919988.001]
  • (PMID = 20720311.001).
  • [ISSN] 2190-3883
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Platelet Membrane Glycoproteins; 0 / RBPJ protein, human; 0 / Receptors, G-Protein-Coupled; 0 / platelet activating factor receptor
  •  go-up   go-down


38. Boscariol M, André KD, Feniman MR: Cleft palate children: performance in auditory processing tests. Braz J Otorhinolaryngol; 2009 Mar-Apr;75(2):213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The average values obtained were 2.16, 2.42, 4.37, 60.50 ms; 40.71 to 67.33%; 96.25 to 99.38%; 73.55 to 73.88% and 58.38 to 65.47% respectively for the MSSNV, MSSV, LS, AFT-R, PSI/SSI tests with ipsilateral (PSI/SSIMCI) and contralateral (PSI/SSI/MCC) competitive message, DD and SSW tests.


39. Huang GS, Chang WC, Lee HS, Taylor JA, Cheng TY, Chen CY: Merkel cell carcinoma arising from the subcutaneous fat of the arm with intact skin. Dermatol Surg; 2005 Jun;31(6):717-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma arising from the subcutaneous fat of the arm with intact skin.
  • BACKGROUND: Merkel cell carcinoma is a rare malignant neuroendocrine neoplasm characteristically arising from the dermis of sunlight-exposed skin.
  • It rarely arises outside the skin.
  • OBJECTIVE: We present a patient with primary Merkel cell carcinoma arising from subcutaneous fat, with no involvement of the overlying skin.
  • METHODS: We report a 63-year-old woman with a primary lesion of Merkel cell carcinoma that arose from the subcutaneous fat layer of the left arm.
  • The lesion presented as a subcutaneous nodule with intact overlying skin.
  • RESULTS: Histopathologic examination confirmed the diagnosis of Merkel cell carcinoma with local lymphatic metastasis, and the lesion was completely located in the subcutaneous fat, with no involvement of the dermis.
  • CONCLUSION: Primary Merkel cell carcinoma may arise from the subcutaneous fat and present as an entirely subcutaneous lesion with intact skin.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Neoplasms, Adipose Tissue / surgery. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996429.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Fakiha M, Letertre P, Vuillez JP, Lebeau J: Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther; 2010 Jul-Sep;6(3):382-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of Merkel cell tumor after somatostatin analog treatment.
  • We recently treated one patient presenting with a disseminated non-operable Merkel cell carcinoma (MCC) by lanreotide (somatostatin analog), with a complete remission of the disease and a follow up of 17 months.
  • We present in this paper a case report with a review of the utilization of somatostatin analogues in the treatment of MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / drug therapy. Remission Induction. Skin Neoplasms / drug therapy. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cancer Res Ther. 2012 Jul-Sep;8(3):460 [23174738.001]
  • (PMID = 21119285.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


41. Suomela S, Koljonen V, Skoog T, Kukko H, Böhling T, Saarialho-Kere U: Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma. Virchows Arch; 2009 Dec;455(6):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an aggressive cutaneous tumor with poor outcome and increasing incidence.
  • We examined by immunohistochemistry the expression of three novel matrix metalloproteinases (MMPs)-MMP-21, MMP-26, and MMP-28-in 44 primary MCC tumors and six lymph node metastases while MMP-10 served as a positive control.
  • Their mRNA expression was also studied in the UISO MCC cell line basally and after various stimulations using quantitative real-time PCR.
  • MMP-28 was observed in tumor cells of 15/44 samples especially in tumors <2 cm in diameter (p = 0.015) while 21/44 specimens showed MMP-28 in the tumor stroma.
  • Expression of MMP-21 was demonstrated in tumor cells of 13/43 samples.
  • MMP-26, instead, was positive in stromal cells (17/44) and its expression associated with tumors >or=2 cm in diameter (p = 0.006).
  • Stromal expression of MMP-10 was the most frequent finding of the studied samples (31/44), but MMP-10 was detected also in tumor cells (17/44).
  • MMP-10, MMP-21, and MMP-28 mRNAs were basally expressed by the UISO cells, and the corresponding proteins were detectable by immunostaining of cultured cells.
  • Our results suggest that novel MMPs may have a role in MCC pathogenesis: especially that MMP-26 expression in stroma is associated with larger tumors with poor prognosis.
  • Expression of MMP-21 and MMP-28 seems to associate with the tumors of lesser malignant potential.
  • We also confirm the previous finding on the role of MMP-10 in MCC pathogenesis.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. Matrix Metalloproteinase 10 / genetics. Matrix Metalloproteinases / genetics. Matrix Metalloproteinases, Secreted / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Lymphatic Metastasis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 May 20;99(3):352-60 [11992403.001]
  • [Cites] J Invest Dermatol. 2005 Apr;124(4):849-56 [15816845.001]
  • [Cites] Tumour Biol. 2006;27(3):133-41 [16641547.001]
  • [Cites] Transplant Proc. 2002 Aug;34(5):1780-1 [12176573.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):35-42 [11232947.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):80-8 [12605370.001]
  • [Cites] J Cutan Med Surg. 2000 Oct;4(4):186-95 [11231196.001]
  • [Cites] Cancer. 1993 Nov 15;72 (10 ):3099-105 [7693327.001]
  • [Cites] Br J Dermatol. 1997 Oct;137(4):637-41 [9390346.001]
  • [Cites] Exp Dermatol. 2006 Oct;15(10):775-83 [16984259.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):907-13 [16730219.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):90-101 [17115023.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Acta Oncol. 1994;33(4):365-9 [8018367.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1887-99 [14691307.001]
  • [Cites] Plast Reconstr Surg. 1997 Feb;99(2):547-53 [9030166.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):503-15 [12617721.001]
  • [Cites] Drugs Aging. 2005;22(3):219-29 [15813655.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):800-8 [17851543.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3856-65 [16940349.001]
  • [Cites] Gene. 2002 Nov 13;301(1-2):31-41 [12490321.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):653-61 [15185874.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] Int J Biochem Cell Biol. 2004 May;36(5):942-56 [15006646.001]
  • [Cites] Mol Aspects Med. 2008 Oct;29(5):290-308 [18619669.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):954-60 [16133364.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 1):715-22 [8227544.001]
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2116-22 [17476292.001]
  • [Cites] Exp Dermatol. 2008 Nov;17(11):897-907 [18803661.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):87-98 [16680575.001]
  • [Cites] J Invest Dermatol. 2002 Jul;119(1):14-21 [12164918.001]
  • [Cites] Histopathology. 2000 May;36(5):415-20 [10792482.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):832-41 [14576661.001]
  • [Cites] Cancer Invest. 2008 Jul;26(6):562-8 [18584346.001]
  • [Cites] J Cutan Pathol. 2009 Sep;36(9):929-36 [19674198.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):497-8 [11853800.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1128-40 [17873896.001]
  • (PMID = 19921252.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.24.- / MMP21 protein, human; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.22 / Matrix Metalloproteinase 10
  •  go-up   go-down


42. Heiskala K, Arola J, Heiskala M, Andersson LC: Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol; 2010 01;25(1):63-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Reg IV and Hath1 in neuroendocrine neoplasms.
  • Reg IV (RELP), a Regenerating protein family member, is constitutively expressed in neuroendocrine cells of the intestinal mucosa.
  • The helix-loop-helix transcription factor Hath1 is the human homologue of murine Math1, which regulates the embryonic differentiation of neural and intestinal secretory lineage cells.
  • Hath1 is constitutively expressed in a subset of mature secretory gastrointestinal cells.
  • We investigated by immunohistochemistry the expression of Reg IV and Hath1 in 63 neuroendocrine tumors.
  • Intestinal neuroendocrine neoplasms showed co-expression of Reg IV and Hath1, as did parathyroidal and Merkel cell tumors.
  • Lung small-cell carcinoma and gastric mucocellular carcinoma expressed only Reg IV.
  • Pancreatic islet-derived tumors, pheochromocytomas, and paragangliomas expressed only Hath1.
  • These distinct expression profiles may be useful for differential diagnostics of metastatic lesions of neuroendocrine tumors.
  • The dissimilar expression patterns suggest that the proteins belong to different signaling pathways and are activated at different stages of neuroendocrine differentiation.
  • Local Reg IV expression may be influenced by the growth factors bFGF and HGF and/or their receptors CD138 and c-met, which were found to co-localize with Reg IV in intestinal neuroendocrine tumors.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Lectins, C-Type / biosynthesis. Neuroendocrine Tumors / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Digestive System / cytology. Epithelial Cells / physiology. Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / cytology. Intestinal Mucosa / metabolism. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Male. Middle Aged. Pheochromocytoma / metabolism. Pheochromocytoma / pathology


43. Ng TC, Chiu KW, Rabie AB, Hägg U: Repeated mechanical loading enhances the expression of Indian hedgehog in condylar cartilage. Front Biosci; 2006;11:943-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated mechanical loading enhances the expression of Indian hedgehog in condylar cartilage.
  • Indian hedgehog (Ihh) acts as a mechanotransduction mediator that converts mechanical strain into cellular proliferation and cartilage formation in mandibular condylar cartilage.
  • The aim of this study was to examine the effect of repeated mechanical strain on the level of expression of Ihh and type II collagen mRNA in condylar growth.
  • Total RNA was extracted from condylar cartilage immediately after dissection.
  • This indicated that mechanical loading in a repeated manner, triggers the expression of Ihh which in turn increases the number of replicating mesenchymal cells as well as the amount of the cartilage formed.
  • Taken together these events increase condylar growth.
  • [MeSH-major] Cartilage / metabolism. Mandibular Condyle / pathology. Stress, Mechanical. Trans-Activators / metabolism
  • [MeSH-minor] Animals. Bone Development. Cell Proliferation. Collagen / metabolism. Collagen Type II. DNA Primers / chemistry. Female. Hedgehog Proteins. Intercellular Signaling Peptides and Proteins / metabolism. Models, Statistical. Polymerase Chain Reaction. RNA / metabolism. RNA, Messenger / metabolism. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Temperature. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146784.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type II; 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / IHH protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 63231-63-0 / RNA; 9007-34-5 / Collagen
  •  go-up   go-down


44. Kim MS, Jung SY, Kang JH, Kim HJ, Ko HM, Jung JY, Koh JT, Kim WJ, Kim SM, Lee EJ, Kim SH: Effects of bisphosphonate on the endochondral bone formation of the mandibular condyle. Anat Histol Embryol; 2009 Oct;38(5):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of bisphosphonate on the endochondral bone formation of the mandibular condyle.
  • The development of the mandibular condylar cartilage is important for the overall growth of the mandible.
  • However, there have been a few researches into medical approaches aimed at controlling condylar growth.
  • This study examined the effects of bisphosphonate on the growth of the condylar cartilage.
  • The total thickness of the cartilage layers was also unaffected by the treatment for 7 days (P > 0.05).
  • In particular, there was no change in the thickness of the perichondrium and reserve cell layer at the measured condylar regions (P > 0.05).
  • However, the thickness of the proliferating cell layer was reduced significantly, whereas the thickness of hypertrophied cartilage layer was increased (P < 0.05).
  • The number of chondroclasts engaged in hypertrophied cartilage resorption was reduced significantly by the alendronate treatment (P < 0.05).
  • These results indicate that alendronate (>3.5 mg/kg/week) inhibits the longitudinal growth of the mandibular condyle by inhibiting chondrocyte proliferation and the resorption of hypertrophied cartilage for ossification.
  • [MeSH-major] Alendronate / pharmacology. Bone Density Conservation Agents / pharmacology. Bone Development / drug effects. Mandibular Condyle / drug effects
  • [MeSH-minor] Animals. Bone Density. Cartilage, Articular / cytology. Drug Administration Schedule. Gene Expression Regulation, Enzymologic / drug effects. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681835.001).
  • [ISSN] 1439-0264
  • [Journal-full-title] Anatomia, histologia, embryologia
  • [ISO-abbreviation] Anat Histol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; EC 3.4.24.35 / Matrix Metalloproteinase 9; X1J18R4W8P / Alendronate
  •  go-up   go-down


45. Li B, Yu SB, Li QH, Wen J, Dong ZW, Wang MQ: [Effect of experimentally created occlusal disorders on the expression of estrogen in rat condylar cartilage]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2009 Oct;27(5):561-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of experimentally created occlusal disorders on the expression of estrogen in rat condylar cartilage].
  • OBJECTIVE: To investigate the effect of experimentally created occlusal disorders (ECOD) on the expression of estrogen in rat condylar cartilage.
  • 1) Estrogen was abundant in mature layer and hypertrophic layer of rat mandibular condylar cartilage.
  • However, the expression in removed occlusal disorder group was higher than that in control group and 8 weeks of ECOD group.
  • CONCLUSION: In rat condylar cartilage, the expression of estrogen de-creases with age.
  • [MeSH-major] Cartilage, Articular. Estrogens
  • [MeSH-minor] Animals. Chondrocytes. Immunohistochemistry. Mandibular Condyle. Molar. Rats. Sexual Maturation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927734.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


46. Brecher AS, Dubord R: Effect of acetaldehyde upon cathepsin G and chymase. NRAS implications. Dig Dis Sci; 2008 May;53(5):1311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of acetaldehyde upon cathepsin G and chymase. NRAS implications.
  • We report here the results of a study on the effect of acetaldehyde upon cathepsin G and mast cell chymase.
  • Acetaldehyde enhanced cathepsin G activity at all of the concentrations tested between 11.2 and 223.5 mM in a statistically significant manner.
  • Chymase activity also is elevated in the presence of 440 mM acetaldehyde and diminished in the presence of 27 mM acetaldehyde.
  • [MeSH-major] Acetaldehyde / pharmacology. Cathepsins / drug effects. Chymases / drug effects. Serine Endopeptidases / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochem Res. 1985 Nov;10(11):1525-32 [3911093.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1994;60:83-5 [7976663.001]
  • [Cites] Alcohol. 1996 Mar-Apr;13(2):125-31 [8814645.001]
  • [Cites] Regul Pept. 1993 Jan 22;43(1-2):1-20 [8426906.001]
  • [Cites] Biochemistry. 1984 Jan 17;23(2):227-32 [6696878.001]
  • [Cites] Clin Sci (Lond). 1979 Dec;57 Suppl 5:295s-298s [540446.001]
  • [Cites] Blood Press. 1998 Nov;7(5-6):316-23 [10321446.001]
  • [Cites] J Recept Signal Transduct Res. 2005;25(1):35-44 [15960393.001]
  • [Cites] J Clin Invest. 1982 Jan;69(1):25-30 [6172448.001]
  • [Cites] Biochem J. 1965 Nov;97(2):540-6 [16749161.001]
  • [Cites] Adv Anat Embryol Cell Biol. 1982;76:1-86 [7124488.001]
  • [Cites] Alcohol Alcohol Suppl. 1991;1:271-6 [1845549.001]
  • [Cites] J Lab Clin Med. 1992 Jul;120(1):35-41 [1613325.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3925-9 [9814470.001]
  • [Cites] Brain Res. 1981 Nov 2;223(2):343-53 [7025965.001]
  • [Cites] Biochemistry (Mosc). 2000 Dec;65(12):1337-45 [11173502.001]
  • [Cites] Hypertension. 2006 Mar;47(3):515-21 [16365192.001]
  • [Cites] Clin Exp Hypertens. 1995 Jan-Feb;17(1-2):251-66 [7735273.001]
  • [Cites] Digestion. 1992;53(1-2):114-20 [1289169.001]
  • [Cites] Hypertens Res. 1995 Mar;18(1):33-7 [7584907.001]
  • [Cites] Rocz Akad Med Bialymst. 2001;46:240-50 [11780568.001]
  • [Cites] Am J Kidney Dis. 2005 Mar;45(3):e45-50 [15754263.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Feb;20(1):47-51 [8651461.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32339-44 [15173164.001]
  • [Cites] Am J Cardiol. 1986 Feb 1;57(4):227-31 [3946213.001]
  • [Cites] Alcohol. 1994 Nov-Dec;11(6):493-9 [7865150.001]
  • [Cites] Am J Hypertens. 1989 Sep;2(9):708-14 [2803676.001]
  • [Cites] J Biol Chem. 1990 Dec 25;265(36):22348-57 [2266130.001]
  • [Cites] J Clin Invest. 1986 Jan;77(1):196-201 [3511089.001]
  • [Cites] J Biol Chem. 1982 Dec 25;257(24):15042-6 [6294088.001]
  • [Cites] Biochemistry. 1980 Dec 9;19(25):5799-804 [7006692.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Aug;17(4):841-6 [8214424.001]
  • [Cites] Alcohol Clin Exp Res. 1985 Mar-Apr;9(2):125-30 [3890591.001]
  • [Cites] Alcohol. 1995 Nov-Dec;12(6):505-9 [8590610.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Jul;28(7):807-21 [8925411.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):36-41 [8689399.001]
  • [Cites] Alcohol. 1993 Nov-Dec;10(6):545-8 [8123215.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 1;397(1):77-83 [11747312.001]
  • [Cites] Clin Exp Hypertens A. 1991;13(3):339-56 [1893609.001]
  • (PMID = 17932768.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.- / Cathepsins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.20 / CTSG protein, human; EC 3.4.21.20 / Cathepsin G; EC 3.4.21.20 / Ctsg protein, rat; EC 3.4.21.39 / Chymases; GO1N1ZPR3B / Acetaldehyde
  •  go-up   go-down


47. Foulongne V, Dereure O, Kluger N, Molès JP, Guillot B, Segondy M: Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol; 2010 Jan;162(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases.
  • Background A novel polyomavirus, the Merkel cell polyomavirus (MCPyV), has recently been identified in Merkel cell carcinoma (MCC).
  • Objectives To investigate the specificity of this association through the detection, quantification and analysis of MCPyV DNA in lesional and nonlesional skin biopsies from patients with MCC or with other cutaneous diseases, as well as in normal skin from clinically healthy individuals.
  • Methods DNA was extracted from lesional and nonlesional skin samples of patients with MCC or with other cutaneous diseases and from normal-appearing skin of clinically healthy subjects.
  • Results MCPyV DNA was detected in 14 of 18 (78%) patients with MCC, five of 18 (28%) patients with other skin diseases (P = 0.007) and one of six (17%) clinically healthy subjects.
  • In patients with MCC, viral DNA was detected in nine of 11 (82%) tumours and in 10 of 14 (71%) nontumoral skin samples (P = 0.66).
  • MCPyV DNA levels were higher in MCC tumours than in nontumoral skin from patients with MCC, and than in lesional or nonlesional skin from patients with other cutaneous disorders.
  • Signature mutations in the T antigen gene were not identified in the two MCC tumour specimens analysed.
  • Conclusions High prevalence and higher levels of MCPyV DNA in MCC supports a role for MCPyV in tumorigenesis.
  • However, the high prevalence of MCPyV in the nontumoral skin and in subjects without MCC suggests that MCPyV is a ubiquitous virus.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. DNA, Viral / isolation & purification. Polyomavirus / genetics. Skin / virology. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Viral, Tumor / genetics. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Sequence Analysis, DNA. Skin Diseases / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678822.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  •  go-up   go-down


48. Calder KB, Coplowitz S, Schlauder S, Morgan MB: A case series and immunophenotypic analysis of CK20-/CK7+ primary neuroendocrine carcinoma of the skin. J Cutan Pathol; 2007 Dec;34(12):918-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case series and immunophenotypic analysis of CK20-/CK7+ primary neuroendocrine carcinoma of the skin.
  • BACKGROUND: The diagnosis of Merkel cell carcinoma (MCC) can be rather challenging; therefore, the immunohistochemical profile is important in confirming the microscopic diagnosis.
  • Characteristic of the neuroendocrine and epithelial differentiation of MCC, antibodies to cytokeratin (CK) 20, CK7, epithelial membrane antigen, and neuron-specific enolase among others, are used in confirming the diagnosis.
  • As reported in the literature, the majority of MCC express CK20 and are CK7 negative.
  • Herein, we present a case series of seven patients with CK20-/CK7+ primary cutaneous neuroendocrine carcinoma.
  • METHODS: All cases of MCC with specific CK20-/CK7+ staining on file at a large Veterans' hospital and tertiary referral dermatopathology service were reviewed.
  • CONCLUSIONS: Herein we have presented a hitherto unreported group of patients with CK20-/CK7+ primary neuroendocrine carcinoma of the skin.
  • The purpose of this case series is to describe a new immunophenotypic variant of MCC, while further expanding the differential diagnosis of tumors included in the subset of neoplasms showing CK20-/CK7+ staining.
  • [MeSH-major] Carcinoma, Merkel Cell / metabolism. Carcinoma, Merkel Cell / pathology. Keratin-20 / metabolism. Keratin-7 / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 Mar;36(3):385-6; author reply 387 [19220637.001]
  • (PMID = 18001414.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


49. Mahooti S, Wakely PE Jr: Cytopathologic features of olfactory neuroblastoma. Cancer; 2006 Apr 25;108(2):86-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathologic features of olfactory neuroblastoma.
  • BACKGROUND: Olfactory neuroblastoma (ONB) is an uncommon neoplasm arising from the olfactory mucosa.
  • Because its cytopathology is largely limited to case reports, the goal was to evaluate a series of ONB cases, compare them with previously reported cases, and with a control group of pulmonary and cutaneous small cell neuroendocrine carcinoma (NEC).
  • METHODS: Six fine-needle aspiration (FNA) biopsies of metastatic ONB and one case with imprint smears of primary ONB were recovered from files.
  • Aspirates from seven FNA cases of metastatic pulmonary small cell NEC and four cases of metastatic Merkel cell carcinoma to the head and neck functioned as a control group and were compared with those of ONB.
  • A correct cytologic diagnosis of metastatic ONB (five cases) or malignant small round cell tumor (one case) was made in six cases.
  • The single primary tumor and five of six metastatic tumors were histologically confirmed.
  • These included high cellularity (seven of seven cases), distribution as single forms and cell clusters (seven of seven cases), a two-cell population of intact and apoptotic nuclei (seven of seven cases), nuclear molding (seven of seven cases), paranuclear 'blue bodies' (five of seven cases), necrosis (five of seven cases), and absence of lymphoglandular bodies (seven of seven cases).
  • Nonetheless, a cytopathologic diagnosis of metastatic ONB can be made with confidence in nearly all patients if a well documented history of ONB exists.
  • Minus such a clinical context, aspirates of metastatic ONB may be mistaken for metastatic pulmonary small cell NEC, cutaneous neuroendocrine (Merkel cell) carcinoma, and even small cell lymphoma.
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / secondary. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology. Scalp. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16456848.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Rodríguez-Prieto MA, Alonso-Alonso T, Toribio-García JA, Mateos-Hernández A: [Young patient with eyelid Merkel carcinoma: Mohs microsurgery versus exenteration]. Arch Soc Esp Oftalmol; 2009 Nov;84(11):581-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Young patient with eyelid Merkel carcinoma: Mohs microsurgery versus exenteration].
  • [Transliterated title] Paciente joven con carcinoma de Merkel palpebral: microcirugía de Mohs versus exenteración.
  • CASE REPORT: We present the case of a 47-year-old female suffering from progeria who developed an eyelid Merkel cell carcinoma (MCC) following cyclosporine treatment for a corneal transplant.
  • Later she had a recurrent tumour for which a wide excision with orbital exenteration was performed.
  • DISCUSSION: MCC is an aggressive tumour that has a larger incidence in elderly people, women and immunosuppressed patients.
  • MMS seems unsuitable for the treatment of MCC; if tumour recurrence occurs a wide resection should be performed (Arch Soc Esp Oftalmol 2009; 84: 581-584).
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Eyelid Neoplasms / surgery. Mohs Surgery. Neoplasms, Second Primary / surgery. Orbit Evisceration. Orbital Neoplasms / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967613.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. Ando M, Ito R, Ozeki Y, Nakayama Y, Nabeshima T: Evaluation of a novel sugar coating method for moisture protective tablets. Int J Pharm; 2007 May 24;336(2):319-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that the crystallized amorphous sucrose after compression at 200 MPa was moisture protective, and the water vapor permeability coefficient was decreased to 1/2000 or less compared with a tablet prepared with a lactose-microcrystalline cellulose (MCC) mixture, hydroxypropylmethylcellulose (HPMC), and sucrose crystal.

  • Hazardous Substances Data Bank. SUCROSE .
  • Hazardous Substances Data Bank. Lactose .
  • Hazardous Substances Data Bank. Water .
  • Hazardous Substances Data Bank. METHYL CELLULOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258875.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Excipients; 0 / Powders; 0 / Tablets; 0 / microcrystalline cellulose; 059QF0KO0R / Water; 3NXW29V3WO / Hypromellose Derivatives; 57-50-1 / Sucrose; 9004-34-6 / Cellulose; 9004-67-5 / Methylcellulose; J2B2A4N98G / Lactose
  •  go-up   go-down


52. Yanagida H, Yamasaki A, Yanagisawa Y: Methodology for predicting OEL from rodent LD50 values for metals and metallic compounds. Environ Sci Technol; 2005 Jan 1;39(1):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The OEL values were predicted from LD50 values and metallic compensation coefficients (MCC), which were developed as the regression coefficients of dummy variables that represented the metallic element contained in the substance of interest.
  • The value of the MCC indicated the extent of the adverse health effects of the metal in the substance.
  • Smaller values of the MCC were assigned to metals that would have the more severe adverse health effects, such as carcinogenesis, while larger values were given to the less toxic metals.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667119.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


53. Zhang X, Tang X, Yang R: Development of a tamsulosin hydrochloride controlled-release capsule consisting of two different coated pellets. Drug Dev Ind Pharm; 2009 Jan;35(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TSH-loaded core pellets consisting of microcrystalline cellulose (MCC), lactose, Carbopol(R) 974P, and the active agent, were prepared by extrusion/spheronization method.

  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. Lactose .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686088.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylates; 0 / Adrenergic alpha-Antagonists; 0 / Capsules; 0 / Delayed-Action Preparations; 0 / Eudragit L 30 D-55; 0 / Eudragit NE 30-D; 0 / Excipients; 0 / Methacrylates; 0 / Polymers; 0 / Sulfonamides; 0 / carbopol 974P NF; 0 / microcrystalline cellulose; 9004-34-6 / Cellulose; G3P28OML5I / tamsulosin; J2B2A4N98G / Lactose
  •  go-up   go-down


54. Chien YH, Hwu WL, Chiang BL: The genetics of atopic dermatitis. Clin Rev Allergy Immunol; 2007 Dec;33(3):178-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic dermatitis (AD) is a complex genetic disorder influenced by environmental factors.
  • RESULTS: This report here is focusing on the current progress in searching the disease-susceptibility genes of AD via both the linkage studies and candidate gene approaches.
  • Genome-wide linkage studies have identified multiple susceptibility loci on 3q and 17q.
  • At least 28 candidate genes have to date been verified in association studies, but only association with genes of interleukin (IL)-4, IL-13, IL-4RA, mast cell chymase, and serine protease inhibitor, kazal-type 5 have been replicated in more than two different studies.
  • The effect of environmental trigger may also have to be considered to elucidate the real face of the disease.
  • [MeSH-major] Dermatitis, Atopic / genetics. Dermatitis, Atopic / immunology. Genetic Predisposition to Disease. Immunologic Factors / genetics. Interleukin-4 / genetics. Interleukin-4 / immunology

  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 2004 Mar;113(3):565-7 [15007364.001]
  • [Cites] Br J Dermatol. 2000 May;142(5):1003-6 [10809862.001]
  • [Cites] J Invest Dermatol. 1994 Jan;102(1):128-37 [8288906.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):813-7 [12704363.001]
  • [Cites] Allergy. 2002 Feb;57(2):160-3 [11929421.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):951-62 [14708592.001]
  • [Cites] Ann Allergy Asthma Immunol. 2004 Oct;93(4):334-8 [15521368.001]
  • [Cites] Allergy. 2000 Jul;55(7):641-6 [10921463.001]
  • [Cites] Hum Genet. 1998 Feb;102(2):236-9 [9521597.001]
  • [Cites] J Allergy Clin Immunol. 2000 May;105(5):1002-7 [10808183.001]
  • [Cites] Clin Exp Allergy. 1998 Feb;28(2):151-5 [9515586.001]
  • [Cites] Clin Exp Immunol. 1997 Jan;107 Suppl 1:25-30 [9020932.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):167-70 [10887320.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):62-6 [15191543.001]
  • [Cites] Int Immunol. 1990;2(7):669-75 [2278997.001]
  • [Cites] J Allergy Clin Immunol. 2003 Sep;112(3):593-8 [13679820.001]
  • [Cites] Immunogenetics. 2005 Feb;56(11):808-17 [15712015.001]
  • [Cites] Immunology. 1999 Mar;96(3):365-71 [10233717.001]
  • [Cites] Allergy. 2001 Sep;56(9):841-9 [11551248.001]
  • [Cites] Hum Hered. 1998 Sep-Oct;48(5):271-4 [9748697.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):470-3 [11101848.001]
  • [Cites] Curr Opin Allergy Clin Immunol. 2005 Feb;5(1):23-9 [15643340.001]
  • [Cites] J Invest Dermatol. 2002 Oct;119(4):870-5 [12406333.001]
  • [Cites] Pharmacogenetics. 2001 Jun;11(4):299-305 [11434507.001]
  • [Cites] Respir Res. 2002;3:7 [11806842.001]
  • [Cites] Infect Immun. 2000 Nov;68(11):6398-401 [11035751.001]
  • [Cites] J Dermatol Sci. 2002 Nov;30(2):161-6 [12413772.001]
  • [Cites] Hum Hered. 1998 Jan-Feb;48(1):38-41 [9463800.001]
  • [Cites] J Neuroimmunol. 2005 Apr;161(1-2):87-92 [15748947.001]
  • [Cites] Nat Genet. 2001 Apr;27(4):372-3 [11279517.001]
  • [Cites] Br J Dermatol. 1998 Jan;138(1):182-7 [9536245.001]
  • [Cites] J Dermatol Sci. 2002 Sep;29(3):222-8 [12234713.001]
  • [Cites] J Clin Invest. 1995 Jan;95(1):211-8 [7814618.001]
  • [Cites] J Immunol. 2000 Feb 1;164(3):1612-6 [10640782.001]
  • [Cites] Br J Dermatol. 2000 Aug;143(2):373-8 [10951148.001]
  • [Cites] J Allergy Clin Immunol. 2004 Feb;113(2):307-14 [14767447.001]
  • [Cites] Chest. 2003 Mar;123(3 Suppl):438S [12629028.001]
  • [Cites] Immunogenetics. 2001 May-Jun;53(4):264-9 [11491529.001]
  • [Cites] J Am Acad Dermatol. 2004 Dec;51(6):899-905 [15583580.001]
  • [Cites] J Invest Dermatol. 2004 Mar;122(3):843-5 [15086575.001]
  • [Cites] Genomics. 1993 Mar;15(3):614-20 [8468056.001]
  • [Cites] Eur J Immunogenet. 2003 Oct;30(5):355-9 [14641544.001]
  • [Cites] J Allergy Clin Immunol. 2001 Aug;108(2):285-7 [11496248.001]
  • [Cites] J Invest Dermatol. 2002 Mar;118(3):436-43 [11874482.001]
  • [Cites] Exp Dermatol. 2004 Nov;13(11):715-9 [15500644.001]
  • [Cites] J Dermatol Sci. 2003 Nov;33(2):130-3 [14581140.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10942-7 [11005866.001]
  • [Cites] J Am Acad Dermatol. 1986 Sep;15(3):487-94 [3760273.001]
  • [Cites] J Appl Genet. 2005;46(1):93-104 [15741670.001]
  • [Cites] Clin Chest Med. 2000 Jun;21(2):245-61 [10907586.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):581-3 [8774571.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):3009-17 [9185525.001]
  • [Cites] Clin Exp Allergy. 2003 Feb;33(2):166-9 [12580907.001]
  • [Cites] Clin Exp Allergy. 1995 Nov;25 Suppl 2:74-8; discussion 95-6 [8590350.001]
  • [Cites] Curr Opin Immunol. 2000 Dec;12(6):641-6 [11102766.001]
  • [Cites] Hum Mol Genet. 2001 Aug 15;10(17):1793-805 [11532989.001]
  • [Cites] J Allergy Clin Immunol. 2000 May;105(5):860-76 [10808164.001]
  • [Cites] Dermatology. 2005;210(2):91-9 [15724090.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):709-17 [12413520.001]
  • [Cites] Clin Exp Allergy. 2004 Mar;34(3):340-5 [15005725.001]
  • [Cites] Clin Exp Allergy. 2002 Aug;32(8):1199-202 [12190659.001]
  • [Cites] Clin Pharmacol Ther. 1999 May;65(5):562-9 [10340922.001]
  • [Cites] J Immunol. 1995 Dec 1;155(11):5184-9 [7594528.001]
  • [Cites] Nat Genet. 2003 Dec;35(4):349-56 [14608357.001]
  • [Cites] J Invest Dermatol. 1999 Jul;113(1):43-8 [10417617.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):5838-44 [11698458.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):119-20 [9620765.001]
  • [Cites] J Allergy Clin Immunol. 2005 Mar;115(3):486-92 [15753894.001]
  • [Cites] Genome Res. 2000 Sep;10(9):1280-7 [10984446.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jun;109(6):980-7 [12063528.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):502-4 [9643293.001]
  • [Cites] J Allergy Clin Immunol. 2001 Aug;108(2):281-4 [11496247.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):187-90 [15202833.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9979-84 [9707586.001]
  • [Cites] Hum Mol Genet. 2002 Jun 15;11(13):1539-48 [12045207.001]
  • [Cites] Int Immunol. 1999 Feb;11(2):297-306 [10069428.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1365-7 [15949016.001]
  • [Cites] Lancet. 1996 Jan 6;347(8993):15-8 [8531541.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2003 Nov-Dec;16(6):386-92 [14528063.001]
  • [Cites] J Dermatol Sci. 2004 Dec;36(3):157-64 [15541637.001]
  • [Cites] Genomics. 2001 Jan 15;71(2):246-51 [11161818.001]
  • [Cites] J Allergy Clin Immunol. 2005 Mar;115(3):636-8 [15753919.001]
  • [Cites] J Allergy Clin Immunol. 1997 Oct;100(4):536-43 [9338549.001]
  • [Cites] J Allergy Clin Immunol. 2005 Apr;115(4):828-33 [15806006.001]
  • [Cites] J Allergy Clin Immunol. 2000 Nov;106(5 Suppl):S192-200 [11080731.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):175-8 [11544479.001]
  • [Cites] Br J Dermatol. 2003 Apr;148(4):665-9 [12752122.001]
  • [Cites] J Hum Genet. 2001;46(11):664-7 [11721886.001]
  • [Cites] J Dermatol Sci. 2002 Nov;30(2):100-7 [12413765.001]
  • [Cites] Int Arch Allergy Immunol. 2003 May;131(1):33-8 [12759487.001]
  • [Cites] J Dermatol Sci. 2001 Feb;25(2):116-26 [11164708.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):146-9 [15656815.001]
  • [Cites] Immunogenetics. 2005 Apr;57(1-2):25-32 [15744536.001]
  • [Cites] Allergy. 2000 Sep;55(9):803-17 [11003444.001]
  • [Cites] Genes Immun. 2005 May;6(3):262-4 [15674390.001]
  • [Cites] Transplantation. 1998 Oct 27;66(8):1014-20 [9808485.001]
  • [Cites] J Invest Dermatol. 2000 Nov;115(5):906-8 [11069631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4581-5 [10200305.001]
  • [Cites] Allergy. 2001 May;56(5):452-3 [11350313.001]
  • [Cites] Genes Immun. 2003 Oct;4(7):515-7 [14551605.001]
  • [Cites] J Am Acad Dermatol. 1993 May;28(5 Pt 1):719-23 [8496415.001]
  • [Cites] Allergy. 1997;52(38 Suppl):14-22; discussion 35-6 [9208054.001]
  • [Cites] Clin Exp Dermatol. 1995 Nov;20(6):462-7 [8857337.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Jun;134 Suppl 1:2-6 [15166476.001]
  • [Cites] Br J Dermatol. 1997 Jan;136(1):1-5 [9039286.001]
  • [Cites] Genes Immun. 2003 Jul;4(5):385-9 [12847555.001]
  • [Cites] Nat Rev Immunol. 2005 Apr;5(4):284-95 [15803148.001]
  • [Cites] Springer Semin Immunopathol. 2004 Feb;25(3-4):335-48 [15007635.001]
  • [Cites] Immunol Today. 1998 Aug;19(8):359-61 [9709503.001]
  • [Cites] Nature. 1999 Nov 25;402(6760 Suppl):B5-11 [10586889.001]
  • [Cites] J Allergy Clin Immunol. 2001 May;107(5):871-7 [11344355.001]
  • [Cites] Intern Med. 2000 Aug;39(8):618-25 [10939534.001]
  • [Cites] Br J Dermatol. 2001 Jan;144(1):24-33 [11167679.001]
  • [Cites] Clin Exp Allergy. 2002 Jul;32(7):990-3 [12100043.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 7;259(2):344-8 [10362511.001]
  • [Cites] Clin Exp Allergy. 2001 Oct;31(10):1522-7 [11678851.001]
  • [Cites] Clin Exp Allergy. 2001 Dec;31(12 ):1867-74 [11737038.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):135-40 [15304337.001]
  • [Cites] Scand J Immunol. 1999 Apr;49(4):447-53 [10219773.001]
  • [Cites] Genes Immun. 2000 Feb;1(3):219-24 [11196715.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):101-6 [11841373.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1 Suppl):84S-88S [7616004.001]
  • [Cites] Clin Exp Allergy. 2001 Jan;31(1):152-4 [11167963.001]
  • [Cites] J Allergy Clin Immunol. 1999 Nov;104(5):1066-70 [10550754.001]
  • [Cites] Clin Exp Allergy. 2004 Jul;34(7):1037-42 [15248847.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1338-41 [7910330.001]
  • [Cites] N Engl J Med. 1997 Dec 11;337(24):1720-5 [9392697.001]
  • [Cites] Clin Exp Dermatol. 2005 Mar;30(2):192-3 [15725257.001]
  • [Cites] J Dermatol Sci. 2003 Nov;33(2):121-6 [14581138.001]
  • [Cites] Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1351-8 [2252253.001]
  • [Cites] Br J Dermatol. 1997 Jun;136(6):838-45 [9217814.001]
  • [Cites] Curr Opin Pulm Med. 2004 Jan;10(1):22-30 [14749602.001]
  • [Cites] Clin Exp Allergy. 1999 Dec;29 Suppl 4:47-51 [10641567.001]
  • [Cites] Clin Dermatol. 2003 Mar-Apr;21(2):134-44 [12706331.001]
  • (PMID = 18163224.001).
  • [ISSN] 1080-0549
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Receptors, Interleukin-4; 207137-56-2 / Interleukin-4
  • [Number-of-references] 137
  •  go-up   go-down


55. Reid AC, Silver RB, Levi R: Renin: at the heart of the mast cell. Immunol Rev; 2007 Jun;217:123-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renin: at the heart of the mast cell.
  • Cardiac mast cells proliferate in cardiovascular diseases.
  • In myocardial ischemia, mast cell mediators contribute to coronary vasoconstriction, arrhythmias, leukocyte recruitment, and tissue injury and repair.
  • In coronary atherosclerosis, mast cell mediators facilitate cholesterol accumulation and plaque destabilization.
  • In cardiac failure, mast cell chymase causes myocyte apoptosis and fibroblast proliferation, leading to ventricular dysfunction.
  • Chymase and tryptase also contribute to fibrosis in cardiomyopathies and myocarditis.
  • In addition, mast cell tumor necrosis factor-alpha promotes myocardial remodeling.
  • Cardiac remodeling and hypertrophy in end-stage hypertension are also induced by mast cell mediators and proteases.
  • We recently discovered that cardiac mast cells contain and release renin, which initiates local angiotensin formation.
  • Angiotensin causes coronary vasoconstriction, arrhythmias, fibrosis, apoptosis, and endothelin release, all demonstrated mechanisms of mast-cell-associated cardiac disease.
  • Our discovery of renin in cardiac mast cells and its release in pathophysiological conditions uncovers an important new pathway in the development of mast-cell-associated heart diseases.
  • [MeSH-major] Mast Cells / immunology. Myocardium / immunology. Renin / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498056.001).
  • [ISSN] 0105-2896
  • [Journal-full-title] Immunological reviews
  • [ISO-abbreviation] Immunol. Rev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK60726; United States / NHLBI NIH HHS / HL / HL34215; United States / NHLBI NIH HHS / HL / HL46403; United States / NHLBI NIH HHS / HL / HL47073; United States / NHLBI NIH HHS / HL / HL73400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  • [Number-of-references] 233
  •  go-up   go-down


56. Kim YE, Hong SH, Kim JW, Lee JY: [Evaluation of Fourier transform near-infrared spectrometer for determination of oxalate in standard urinary solution]. J Prev Med Public Health; 2006 Mar;39(2):165-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The determination of oxalate in urine is required for the diagnosis and treatment of primary hyperoxaluria, idiopathic stone disease and various intestinal diseases.
  • METHODS: The range of oxalate concentration in standard urine solutions was 0-221 mg/l.
  • Furthermore, the MCC (multiple correlation coefficient) was 0.998, which was compatible with the 0.923 or 0.999 obtained from the previous enzymatic methods.
  • CONCLUSIONS: These results showed that FT-NIR spectroscopy can be used for rapid determination of the concentration of oxalate in human urine samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615272.001).
  • [ISSN] 1975-8375
  • [Journal-full-title] Journal of preventive medicine and public health = Yebang Ŭihakhoe chi
  • [ISO-abbreviation] J Prev Med Public Health
  • [Language] kor
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Oxalates
  •  go-up   go-down


57. Lenormand C, Pelletier C, Goeldel AL, Chenard MP, Grange F: Second malignant neoplasm occurring years after hyperthermic isolated limb perfusion for melanoma. Arch Dermatol; 2010 Mar;146(3):319-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBSERVATIONS: We describe 2 cases of secondary rare cancers in 2 elderly women: 1 fatal pleomorphic sarcoma and 1 Merkel cell carcinoma, which developed on the same limb 16 years after HILP for melanoma.
  • The risk-benefit balance of high-dose local chemotherapy should be carefully evaluated in the light of these findings, especially in patients with early-stage melanoma or other non-life-threatening medical conditions.
  • [MeSH-major] Carcinoma, Merkel Cell / etiology. Hyperthermia, Induced / adverse effects. Melanoma / therapy. Neoplasms, Second Primary / etiology. Perfusion / adverse effects. Sarcoma / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Fatal Outcome. Female. Follow-Up Studies. Humans. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231505.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Lillis J, Ceilley RI, Nelson P: Merkel cell carcinoma in a patient with autoimmune hepatitis. J Drugs Dermatol; 2005 May-Jun;4(3):357-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a patient with autoimmune hepatitis.
  • Merkel cell carcinoma (MCC) has been shown to have a higher incidence in many etiologically distinct immunosuppressed populations.
  • We report a case of aggressive MCC diagnosed in a man with autoimmune hepatitis who was treated with immunosuppressive therapy for more than 30 years.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Hepatitis, Autoimmune / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Autoimmune Hepatitis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898293.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


59. Serratoni M, Newton M, Booth S, Clarke A: Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system. Eur J Pharm Biopharm; 2007 Jan;65(1):94-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One type of pellets contained the drugs mixed with lactose and microcrystalline cellulose (MCC) and the other types of pellets contained the model drugs dissolved in a self-emulsifying system (4.8%) consisting of equal parts of mono-diglycerides and polysorbate 80 and MCC.
  • Dissolution experiments established that the presence of the self-emulsifying system enhanced the drug release of both model drugs and that the film coating considerably reduced the drug release from pellets made with just water, lactose and MCC.

  • MedlinePlus Health Information. consumer health - Medicines.
  • Hazardous Substances Data Bank. Lactose .
  • Hazardous Substances Data Bank. Water .
  • Hazardous Substances Data Bank. ETHYLCELLULOSE .
  • Hazardous Substances Data Bank. METHYL CELLULOSE .
  • Hazardous Substances Data Bank. PROPYLPARABEN .
  • Hazardous Substances Data Bank. METHYLPARABEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056237.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Capsules; 0 / Delayed-Action Preparations; 0 / Diglycerides; 0 / Emulsions; 0 / Excipients; 0 / Monoglycerides; 0 / Parabens; 0 / Pharmaceutical Preparations; 0 / Polysorbates; 0 / microcrystalline cellulose; 059QF0KO0R / Water; 3NXW29V3WO / Hypromellose Derivatives; 9004-34-6 / Cellulose; 9004-57-3 / ethyl cellulose; 9004-67-5 / Methylcellulose; A2I8C7HI9T / methylparaben; J2B2A4N98G / Lactose; Z8IX2SC1OH / propylparaben
  •  go-up   go-down


60. Yilmaz B, Ozçelik TB, Wee AG: Effect of repeated firings on the color of opaque porcelain applied on different dental alloys. J Prosthet Dent; 2009 Jun;101(6):395-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Seven different types of metal ceramic alloys (3 base metals: Metalloy CC, chromium cobalt (B-MCC); Heraenium NA, nickel chromium (B-HNA); Argeloy NP, nickel chromium beryllium (B-ANP); 3 noble metals: Ceradelta, palladium silver (N-CD); Cerapall 2, palladium (N-CP2); V-Delta SF, gold palladium (N-VDSF); and 1 high noble metal: V-Gnathos Plus, gold platinum (HN-GP)) were used to support a 0.1-mm-thick layer of opaque porcelain (IPS d.SIGN Opaquer, shade B1) to determine the metal alloys' effect on the opaque porcelain color after repeated porcelain firings.
  • Delta E values showed that B-MCC after the first dentin firing, N-CD after the second dentin firing and glaze firing, and B-ANP after the third and fourth dentin firings showed significantly different DeltaE values than all remaining test alloys (P<.001).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463667.001).
  • [ISSN] 1097-6841
  • [Journal-full-title] The Journal of prosthetic dentistry
  • [ISO-abbreviation] J Prosthet Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metal Ceramic Alloys; 0 / Metals; 12001-21-7 / Dental Porcelain
  •  go-up   go-down


61. Hall G, Duncan A, Azurdia R, Leonard N: Lymphoepithelioma-like carcinoma of the skin: a case with lymph node metastases at presentation. Am J Dermatopathol; 2006 Jun;28(3):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma of the skin: a case with lymph node metastases at presentation.
  • We report a case of a primary lymphoepithelioma-like carcinoma (LELC) of the skin.
  • He also had axillary node clearance for metastatic disease.
  • The tumor was composed of islands of pleomorphic cells with a lymphocytic infiltrate.
  • Differential diagnoses included squamous cell carcinoma, adnexal carcinoma, Merkel cell tumors, lymphoepithelial lesions, lymphomas, and skin metastases.
  • The histopathologic and immunohistochemical features were those of a LELC of the skin.
  • Just over 30 cases of primary LELCs arising in the skin have been reported with only 1 documented fatality.
  • [MeSH-major] Carcinoma / pathology. Neovascularization, Pathologic / pathology. Rare Diseases / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Merkel Cell / pathology. Diagnosis, Differential. Humans. Lymphatic Metastasis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Male

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778488.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Manten J, Rijk M, Jansen R: Merkel cell carcinoma; a rare, aggressive, cutaneous malignancy. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma; a rare, aggressive, cutaneous malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21686689.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027524
  •  go-up   go-down


63. Grabowski J, Saltzstein SL, Sadler GR, Tahir Z, Blair S: A comparison of merkel cell carcinoma and melanoma: results from the california cancer registry. Clin Med Oncol; 2008;2:327-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of merkel cell carcinoma and melanoma: results from the california cancer registry.
  • INTRODUCTION: Melanoma and Merkel cell carcinoma (MCC) are both aggressive skin malignancies associated with immunosuppression and possible UV exposure.
  • Both tumors get similar surgical treatment; however, MCC is a relatively rare tumor in which less is known about prognosis and clinical behavior.
  • METHODS: The California Cancer Registry (CCR), a population-based registry, was reviewed from the years 1988-2003.
  • Merkel cell carcinoma and melanoma were compared with relation to gender, age, ethnicity, disease stage, site, and survival.
  • RESULTS: A total of 113,187 cases of melanoma and 1,878 cases of MCC were identified in the CCR.
  • Though both cancers are more common in men than in women, MCC had a higher incidence in men than melanoma (63% vs 57% p < 0.005).
  • MCC occurs in the more elderly, with 73.6% of cases occurring in people over 70 years.
  • MCC shows a predilection for the head and neck compared to melanoma (47% vs 25.8%) Additionally, melanoma occurs more frequently on the trunk than MCC (30% vs 8.7%).
  • Finally, the 10-year cumulative survival is lower for MCC than for melanoma (17.7% vs 61.3%, p < 0.005).
  • CONCLUSION: Many clinicians assume MCC and melanoma behave similarly.
  • However, MCC occurs in an older population, more frequently on the head and neck, in a higher percentage of men.
  • Additionally, MCC has a higher rate of regional metastasis and thus may have more of a benefit from regional staging procedures.
  • Overall, MCC has a worse prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] J Cancer Educ. 2000 Spring;15(1):38-40 [10730802.001]
  • [Cites] Stat Med. 2000 Jul 15;19(13):1729-40 [10861774.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):755-67 [11050578.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] Dermatol Surg. 1999 Jan;25(1):23-5 [9935088.001]
  • [Cites] J Cancer Educ. 2002 Spring;17(1):7-11 [12000111.001]
  • [Cites] Head Neck. 2002 Nov;24(11):982-8 [12410532.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4371-6 [14645427.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):593-9 [15465461.001]
  • [Cites] Am J Clin Oncol. 2004 Oct;27(5):510-5 [15596922.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2300-9 [15800320.001]
  • [Cites] World J Surg Oncol. 2006;4:7 [16466578.001]
  • [Cites] J Cancer Educ. 2005 Winter;20(4):240-6 [16497137.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):78-80 [16875943.001]
  • [Cites] J Cancer Educ. 1990;5(2):85-9 [2206936.001]
  • [Cites] J Dermatol Surg Oncol. 1977 Jan-Feb;3(1):30-1 [325045.001]
  • [Cites] J Natl Cancer Inst. 1984 Jul;73(1):75-82 [6588237.001]
  • [Cites] Am J Epidemiol. 1995 May 15;141(10):923-33 [7741122.001]
  • [Cites] Melanoma Res. 1994 Apr;4(2):79-85 [8069100.001]
  • [Cites] J Cancer Educ. 1993 Winter;8(4):313-8 [8186082.001]
  • [Cites] Aust N Z J Surg. 1998 May;68(5):354-8 [9631909.001]
  • (PMID = 21892294.001).
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P60 MD000220; United States / NCI NIH HHS / CA / R25 CA065745; United States / NCI NIH HHS / CA / U56 CA092079; United States / NCI NIH HHS / CA / U56 CA092081
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161663
  • [Keywords] NOTNLM ; california cancer registry / melanoma / merkel cell carcinoma / skin cancer
  •  go-up   go-down


64. Guihard S, Noël G: [Merkel cell carcinoma, role of radiotherapy and literature review]. Cancer Radiother; 2009 Jan;13(1):47-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma, role of radiotherapy and literature review].
  • [Transliterated title] Les tumeurs à cellules de Merkel, rôle de la radiothérapie. Analyse de la littérature.
  • Merkel cell carcinoma (MCC) is a rare neuroendocrine carcinoma of the skin with features of epithelial differentiation.
  • MCC is chemosensitive but rarely chemocurable in patients with metastasis or locally advanced tumors.
  • [MeSH-major] Carcinoma, Merkel Cell / radiotherapy. Skin Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18718802.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 63
  •  go-up   go-down


65. Duprat JP, Domingues AL, Coelho EG, Leal RM, Nishinari K, Neves RI: Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma. Eur J Surg Oncol; 2009 Jun;35(6):568-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma.
  • INTRODUCTION: Merkel cell carcinoma (MCC) is a very rare and aggressive neoplasm.
  • Due to its rarity, therapeutic guidelines are not well established, especially for regionally advanced disease.
  • Hyperthermic isolated limb perfusion (HILP) with Melphalan and either with or without tumor necrosis factor-alpha (TNF-alpha) is becoming more common in clinical practice, yet the long-term response is not clear.
  • Previous reports have established indications for treatment of unresectable MCC as well as the outcome of MCC patients receiving perfusion treatment in combination with other therapies (e.g., radiation).
  • METHOD: A review was performed of the most important articles in MEDLINE from the last 20 years related to HILP and MCC.
  • Details of one case of MCC where HILP was administered was included in the literature review.
  • RESULTS: A total of nine cases of MCC receiving ILP were identified in the literature; of these, seven achieved a complete response, one a partial response and one no response.
  • CONCLUSION: Based on the cases described, isolated limb perfusion is an acceptable option to treat regional advanced cases of MCC, and the use of TNF-alpha does not impact the overall response.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Merkel Cell / drug therapy. Melphalan / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Chemotherapy, Cancer, Regional Perfusion. Extremities. Fatal Outcome. Female. Groin. Humans. Hyperthermia, Induced. Lymph Node Excision. Lymphatic Metastasis. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19013049.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Number-of-references] 26
  •  go-up   go-down


66. Baumbach JI: Ion mobility spectrometry coupled with multi-capillary columns for metabolic profiling of human breath. J Breath Res; 2009 Sep;3(3):034001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, ion mobility spectrometry (IMS) started to be used for direct breath analysis with respect to metabolic profiling, biomarker finding and gas trace analysis.
  • To enhance the resolution, pre-separation by multi-capillary columns (MCCs) is discussed and examples for IMS chromatograms are presented.
  • The focus is to review the analytical method IMS with respect to potential use for direct investigations of humid air in direct breath analysis but not on detailed discussion of results of specific medical application of MCC/IMS or on specific analytes found in exhaled air.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383463.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Hallahan DE, Kessinger A, Lee NY, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Oseroff AR, Perlis CS, Rosenberg EW, Shaha AR, Urist MM, Wang LC, NCCN Merkel Cell Carcinoma Panel: Merkel cell carcinoma. J Natl Compr Canc Netw; 2009 Mar;7(3):322-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19401064.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


68. Saito A, Tsutsumida A, Furukawa H, Saito N, Mol W, Sekido M, Sasaki S, Oashi K, Kimura C, Yamamoto Y: Merkel cell carcinoma of the face: an analysis of 16 cases in the Japanese. J Plast Reconstr Aesthet Surg; 2009 Oct;62(10):1272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma of the face: an analysis of 16 cases in the Japanese.
  • BACKGROUND: There is no agreement regarding a staging system and optimal treatment of Merkel cell carcinoma.
  • OBJECTIVE: The purpose of this study was to retrospectively review our experience with the surgical treatment of MCC of the face in the Japanese and to study its management and outcome using the staging system described by Clark et al.
  • Patients and tumour characteristics, treatment variables and outcome were analysed.
  • CONCLUSION: This staging system was suggested to reflect prognosis although the number of patients in this series was small.
  • Sentinel lymph node biopsy should be considered to determine the accurate nodal staging, and patients with MCC of the head and neck may be treated according to the revised staging system by Clark et al.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Face. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676193.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


69. Koljonen V, Tukiainen E, Haglund C, Böhling T: Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathology; 2006 Nov;49(5):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / secondary. Ki-67 Antigen / analysis. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Proliferation. Disease Progression. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064309.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


70. Wang Q, Dooner HK: Remarkable variation in maize genome structure inferred from haplotype diversity at the bz locus. Proc Natl Acad Sci U S A; 2006 Nov 21;103(47):17644-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unexpectedly large differences among haplotypes were first revealed in a comparison of the bz genomic regions of two different inbred lines, McC and B73.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2000 Jun;10(6):866-73 [10854418.001]
  • [Cites] Plant Cell. 2005 Nov;17(11):2859-72 [16227451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8903-8 [11438686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8714-9 [11447285.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9161-6 [11470895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11479-84 [11562485.001]
  • [Cites] Genome Res. 2001 Nov;11(11):1817-25 [11691845.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1082-7 [11792865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6080-4 [11983901.001]
  • [Cites] Genome Res. 2002 Jul;12(7):1075-9 [12097344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9573-8 [12060715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12959-62 [12244216.001]
  • [Cites] Plant Cell. 2003 Feb;15(2):381-91 [12566579.001]
  • [Cites] Mol Biol Evol. 2003 Apr;20(4):528-40 [12654934.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9055-60 [12853580.001]
  • [Cites] Genetics. 2003 Dec;165(4):2117-28 [14704191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):700-7 [14701910.001]
  • [Cites] Plant Cell. 2004 May;16(5):1105-14 [15075398.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2304-12 [16079248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12404-10 [15240870.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):569-73 [15457261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101(40):14349-54 [15388850.001]
  • [Cites] Biochem Genet. 1983 Aug;21(7-8):667-89 [6226281.001]
  • [Cites] Genetics. 1988 May;119(1):185-97 [3396861.001]
  • [Cites] Genetics. 1995 Dec;141(4):1573-81 [8601495.001]
  • [Cites] Science. 1996 Nov 1;274(5288):765-8 [8864112.001]
  • [Cites] Genetics. 1997 Jul;146(3):1101-13 [9215911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4441-6 [9539756.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):43-5 [9731528.001]
  • [Cites] Nature. 1999 Mar 18;398(6724):236-9 [10094045.001]
  • [Cites] J Mol Evol. 1999 Jun;48(6):684-91 [10229572.001]
  • [Cites] Ann Bot. 2005 Jan;95(1):127-32 [15596462.001]
  • [Cites] Plant Cell. 2005 Feb;17(2):343-60 [15659640.001]
  • [Cites] Plant Mol Biol. 2005 Jan;57(1):115-27 [15821872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9068-73 [15951422.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):9993-4 [16009929.001]
  • [Cites] Nat Genet. 2005 Sep;37(9):997-1002 [16056225.001]
  • [Cites] Genetics. 2005 Aug;170(4):1929-44 [15937141.001]
  • [Cites] Genome Res. 2000 Jul;10(7):908-15 [10899140.001]
  • (PMID = 17101975.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ493646/ DQ493647/ DQ493648/ DQ493649/ DQ493650/ DQ493651/ DQ493652/ DQ493653/ DQ493654/ DQ493655
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retroelements
  • [Other-IDs] NLM/ PMC1693800
  •  go-up   go-down


71. Murín R, Verleysdonk S, Rapp M, Hamprecht B: Immunocytochemical localization of 3-methylcrotonyl-CoA carboxylase in cultured ependymal, microglial and oligodendroglial cells. J Neurochem; 2006 Jun;97(5):1393-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical localization of 3-methylcrotonyl-CoA carboxylase in cultured ependymal, microglial and oligodendroglial cells.
  • To evaluate the ability of ependymal, microglial and oligodendroglial cells to degrade leucine, the presence of 3-methylcrotonyl-CoA carboxylase (MCC) was investigated in cultures of these cells.
  • MCC is a biotin-containing heterodimeric enzyme that is specific for the irreversible part of the leucine catabolic pathway.
  • It has been reported previously that in cell culture MCC is expressed in astrocytes and a subpopulation of neurones.
  • In the present study ependymal, microglial and oligodendroglial cell cultures, derived from the brains of newborn rats, were examined for the expression of MCC by RT-PCR, western blotting and immunocytochemistry.
  • The results of RT-PCR and western blotting showed the presence of mRNA as well as protein of both subunits of MCC in ependymal, microglial and oligodendroglial cell cultures.
  • Immunocytochemical investigation of the cellular and subcellular distribution of MCC demonstrated a mitochondrial location of MCC in all neuroglial cell types investigated.
  • The ubiquitous expression of MCC in glial cells demonstrates the ability of the cells to engage in the catabolism of leucine transported into the brain, mainly for the generation of energy.
  • [MeSH-minor] Animals. Animals, Newborn. Cells, Cultured. Energy Metabolism / physiology. Immunohistochemistry. Leucine / metabolism. Mitochondria / enzymology. Protein Subunits / genetics. Protein Subunits / metabolism. RNA, Messenger / metabolism. Rats. Rats, Wistar

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Leucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16696850.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / RNA, Messenger; EC 6.4.- / Carbon-Carbon Ligases; EC 6.4.1.4 / methylcrotonoyl-CoA carboxylase; GMW67QNF9C / Leucine
  •  go-up   go-down


72. Jiao K, Wang MQ, Niu LN, Dai J, Yu SB, Liu XD, Wang GW: Death and proliferation of chondrocytes in the degraded mandibular condylar cartilage of rats induced by experimentally created disordered occlusion. Apoptosis; 2009 Jan;14(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death and proliferation of chondrocytes in the degraded mandibular condylar cartilage of rats induced by experimentally created disordered occlusion.
  • OBJECTIVE: To investigate the effect of experimentally created disordered occlusion (ECDO) on cell death and proliferation in rat mandibular condylar cartilage.
  • RESULTS: Time- and sex-related progressive histologic degradation was observed in the condylar cartilage of ECDO rats, accompanied with diminished chondrocyte proliferation in the female 12-week ECDO subgroup (P < 0.05).
  • CONCLUSION: ECDO induces degradation in the rat condylar cartilage accompanied by an increase in chondrocyte death.
  • [MeSH-major] Apoptosis. Cartilage / metabolism. Chondrocytes / chemistry. Mandibular Condyle / metabolism
  • [MeSH-minor] Animals. Cell Death. Cell Proliferation. Female. Immunohistochemistry. In Situ Nick-End Labeling. Male. Osteoarthritis / pathology. Rats. Rats, Sprague-Dawley. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19052875.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Scott DR: Apparent response of cutaneous Merkel cell tumor to topical imiquimod. Cutis; 2006 Feb;77(2):109-10; author reply 110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent response of cutaneous Merkel cell tumor to topical imiquimod.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cutis. 2004 Dec;74(6):350-6 [15663071.001]
  • (PMID = 16570674.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


74. Schmitt W, Ramp U: [Merkel cell carcinoma of the upper lid]. Mund Kiefer Gesichtschir; 2006 Nov;10(6):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma of the upper lid].
  • [Transliterated title] Das Merkel-Zell-Karzinom des Oberlides.
  • AIMS: Merkel cell carcinoma (MCC) of the skin is a rare form of cutaneous malignancy of neuroendocrine origin with a propensity to form cutaneous and lymphogenous metastases.
  • The tumor, affecting predominately elderly patients, has a significantly higher incidence in female patients (80%) compared to male patients (20%).
  • CASE REPORT: A case of a 78-year-old patient with a MCC of the upper lid without lymph node involvement or distant metastasis is described.
  • The tumor was resected and the defect closed by a temporal skin flap performing a temporary cantholysis.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Eyelid Neoplasms / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1993 Feb;16(1):54-7 [8424405.001]
  • [Cites] Dtsch Med Wochenschr. 1997 Jun 6;122(23):753-6 [9229553.001]
  • [Cites] Front Radiat Ther Oncol. 2006;39:68-74 [16394670.001]
  • [Cites] Am J Clin Oncol. 1993 Apr;16(2):102-4 [7680840.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 Sep;19(5):546-51 [16164706.001]
  • [Cites] Hautarzt. 1998 Oct;48 Suppl 1:S27-9 [9866045.001]
  • [Cites] Chirurg. 2001 Apr;72(4):396-401 [11357530.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):881-5 [9307187.001]
  • [Cites] J Surg Oncol. 2005 Jan 1;89(1):1-4 [15611998.001]
  • (PMID = 17028844.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Miyanji F, Furlan JC, Aarabi B, Arnold PM, Fehlings MG: Acute cervical traumatic spinal cord injury: MR imaging findings correlated with neurologic outcome--prospective study with 100 consecutive patients. Radiology; 2007 Jun;243(3):820-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three quantitative (maximum spinal cord compression [MSCC], maximum canal compromise [MCC], and lesion length) and six qualitative (intramedullary hemorrhage, edema, cord swelling, soft-tissue injury [STI], canal stenosis, and disk herniation) imaging parameters were studied.
  • RESULTS: Patients with complete motor and sensory SCIs had more substantial MCC (P=.005), MSCC (P=.002), and lesion length (P=.005) than did patients with incomplete SCIs and those with no SCIs.
  • Patients with complete SCIs also had higher frequencies of hemorrhage (P<.001), edema (P<.001), cord swelling (P=.001), stenosis (P=.01), and STI (P=.001). MCC (P=.012), MSCC (P=.014), and cord swelling (P<.001) correlated with baseline ASIA motor scores. MSCC (P=.028), hemorrhage (P<.001), and cord swelling (P=.029) were predictive of the neurologic outcome at follow-up.
  • [MeSH-major] Cervical Vertebrae / injuries. Magnetic Resonance Imaging / methods. Nervous System Diseases / diagnosis. Nervous System Diseases / etiology. Risk Assessment / methods. Spinal Cord Injuries / complications. Spinal Cord Injuries / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Reproducibility of Results. Risk Factors. Sensitivity and Specificity. Statistics as Topic


76. Nashan D, Radny P, Kösters NC, Nashan B: [Skin tumors in organ-transplant recipients]. Hautarzt; 2007 Jan;58(1):48-50, 52-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin tumors in organ-transplant recipients].
  • Skin cancers are a significant medical problem for organ-transplant recipients.
  • Squamous cell carcinoma and basal cell carcinoma are most common tumors.
  • An increasing incidence of melanoma, Kaposi sarcoma, Merkel cell carcinoma, as well as uncommon skin malignancies, is also seen.
  • Predisposing factors include cumulative sun exposure, cumulative immunosuppression, age, gender, skin type, virus detection and genetic alterations.
  • Skin tumors grow rapidly and their number continues to increase in the years following transplantation.
  • Large numbers of tumors, aggressive courses and appearance in young patients are other characteristics of these skin tumors.
  • In addition standardized registries are needed to assure the comparability of data, to better correlate immunosuppression with skin tumors and to plan therapeutic studies.
  • [MeSH-major] Carcinoma / epidemiology. Melanoma / epidemiology. Risk Assessment / methods. Skin Neoplasms / epidemiology. Transplants / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Derm Venereol. 1992;72(2):115-9 [1350395.001]
  • [Cites] Transplant Proc. 1999 Sep;31(6):2317-8 [10500596.001]
  • [Cites] Transplant Proc. 1995 Aug;27(4):2450-1 [7652877.001]
  • [Cites] Transplant Proc. 1996 Apr;28(2):876-8 [8623443.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):978-82 [16103326.001]
  • [Cites] Br J Dermatol. 1993 Sep;129(3):242-9 [8286220.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1871-4 [16166520.001]
  • [Cites] Circulation. 2000 Nov 7;102(19 Suppl 3):III222-7 [11082391.001]
  • [Cites] Lancet. 1997 Oct 25;350(9086):1193-8 [9652559.001]
  • [Cites] JAMA. 2005 Sep 28;294(12):1476-80 [16189357.001]
  • [Cites] Nephron. 1996;73(2):131-6 [8773333.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1260-2 [10083562.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1758-64 [10223570.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86 [10025742.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):27-34 [9922009.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):962-3 [15848591.001]
  • [Cites] Cutis. 2004 Nov;74(5 Suppl):4-9 [15603215.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):301-6 [12622621.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Arch Dermatol. 1986 Nov;122(11):1288-93 [3535683.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):604-9 [15061843.001]
  • [Cites] Transplant Proc. 1998 Sep;30(6):2768-70 [9745563.001]
  • [Cites] Transplant Proc. 1994 Oct;26(5):2493-8 [7940765.001]
  • [Cites] Transpl Int. 2004 Jul;17(6):279-85 [15221123.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] Hautarzt. 2002 Aug;53(8):524-33 [12221466.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1120 [10083500.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):623-8 [9500317.001]
  • (PMID = 16758224.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


77. DeMond AL, Starr T, Dustin ML, Groves JT: Control of antigen presentation with a photoreleasable agonist peptide. J Am Chem Soc; 2006 Dec 6;128(48):15354-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunological synapse is a specialized intercellular junction between a T cell and a target cell that orchestrates the engagement of receptors and ligands in space and time as a means of regulating function.
  • Here we introduce a reagent for controlling the spatial and temporal presentation of natural antigen to T cells.
  • Moth cytochrome c (88-103) peptide (MCC), an agonist to the murine T cell receptor AND when presented in the context of H2 IEk major histocompatibility complex (IEk), was synthesized with the side-chain amine of Lys99 conjugated to a photosensitive protecting group, 6-nitroveratryloxycarbonyl (NVOC).
  • Cells plated on supported bilayers displaying mobile intercellular adhesion molecule-1 (ICAM-1) and NVOC-MCC loaded IEk did not form immunological synapses and exhibited low intracellular calcium levels, similar to cells presented with self-peptide.
  • [MeSH-minor] Animals. Calcium Signaling. Lipid Bilayers. Major Histocompatibility Complex / immunology. Photochemistry. Receptors, Antigen, T-Cell / immunology. Ultraviolet Rays

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131984.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI044931
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipid Bilayers; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


78. Majewska H, Biernat W: Merkel cell carcinoma. Pathological and molecular aspects of diagnosis and clinical features. Pol J Pathol; 2010;61(3):117-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma. Pathological and molecular aspects of diagnosis and clinical features.
  • Merkel cell carcinoma (MCC) is an aggressive neoplasm of the skin usually developing in the elderly.
  • The morphological and phenotypical characteristics of Merkel cell carcinoma was recently expanded by the molecular profile.
  • The current review is a compilation of these data, which may enable better understanding of the histogenesis and potential target therapy in this rare tumour of the skin.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 6. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Prognosis. Rare Diseases

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225493.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Hu J, Yan C: Identification of deleterious non-synonymous single nucleotide polymorphisms using sequence-derived information. BMC Bioinformatics; 2008;9:297
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: As the number of non-synonymous single nucleotide polymorphisms (nsSNPs), also known as single amino acid polymorphisms (SAPs), increases rapidly, computational methods that can distinguish disease-causing SAPs from neutral SAPs are needed.
  • Many methods have been developed to distinguish disease-causing SAPs based on both structural and sequence features of the mutation point.
  • In this study, we explore the feasibility of classifying SAPs into disease-causing and neutral mutations using only information derived from protein sequence.
  • Using the selected features, a decision tree method can achieve 82.6% overall accuracy with 0.607 Matthews Correlation Coefficient (MCC) in cross-validation.
  • When tested on an independent set that was not seen by the method during the training and feature selection, the decision tree method achieves 82.6% overall accuracy with 0.604 MCC.
  • We also evaluated the proposed method on all SAPs obtained from the Swiss-Prot, the method achieves 0.42 MCC with 73.2% overall accuracy.
  • Different from previous studies, in which only a small set of features were arbitrarily chosen and considered, here we used an automated method to systematically discover useful features from a large set of features well-annotated in public databases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2550-5 [10706611.001]
  • [Cites] Bioinformatics. 2007 Jun 15;23(12):1444-50 [17384424.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):308-11 [11125122.001]
  • [Cites] J Mol Biol. 2001 Mar 23;307(2):683-706 [11254390.001]
  • [Cites] Genome Res. 2001 May;11(5):863-74 [11337480.001]
  • [Cites] Genome Res. 2002 Mar;12(3):436-46 [11875032.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):577-81 [12754702.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Bioinformatics. 2003 Nov 22;19(17):2199-209 [14630648.001]
  • [Cites] Proteins. 2003 Dec 1;53(4):806-16 [14635123.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D516-9 [14681471.001]
  • [Cites] Hum Mutat. 2004 May;23(5):464-70 [15108278.001]
  • [Cites] Nature. 2004 May 27;429(6990):453-6 [15164070.001]
  • [Cites] J Mol Evol. 1984-1985;21(2):112-25 [6100188.001]
  • [Cites] Proteins. 1990;8(2):173-8 [2235995.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9 [1438297.001]
  • [Cites] Nucleic Acids Res. 1999 Jan 1;27(1):355-7 [9847227.001]
  • [Cites] Nucleic Acids Res. 1999 Jan 1;27(1):368-9 [9847231.001]
  • [Cites] Genome Res. 1998 Dec;8(12):1229-31 [9872978.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2185-90 [15746281.001]
  • [Cites] J Mol Biol. 2005 Oct 21;353(2):459-73 [16169011.001]
  • [Cites] Proteins. 2005 Dec 1;61(4):878-87 [16208716.001]
  • [Cites] BMC Bioinformatics. 2006;7:217 [16630345.001]
  • [Cites] Bioinformatics. 2006 Nov 15;22(22):2729-34 [16895930.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D247-52 [17130144.001]
  • [Cites] Nucleic Acids Res. 2007;35(11):3823-35 [17526529.001]
  • [Cites] Bioinformatics. 2000 May;16(5):412-24 [10871264.001]
  • (PMID = 18588693.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2446391
  •  go-up   go-down


80. Rudraraju VS, Wyandt CM: Rheology of Microcrystalline Cellulose and Sodiumcarboxymethyl Cellulose hydrogels using a controlled stress rheometer: part II. Int J Pharm; 2005 Mar 23;292(1-2):63-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rheological properties of two different commercial grades of Microcrystalline Cellulose/Sodiumcarboxymethyl Cellulose (MCC/NaCMC) hydrogels were investigated.
  • Viscoelastic characterization of the hydrogels using a controlled stress rheometer revealed that structure formation in the gels could be detected at a concentration as low as 1.0% w/w MCC/NaCMC in purified water.
  • The elastic modulus (G') and the linear viscoelastic region (LVR) increased with increase in hydrogel concentration.
  • The frequency sweep study of the hydrogels exhibited a flat G', indicating a stable structure at 1.5% w/w and 2.0% w/w concentrations.
  • The oscillation time sweep study indicated that the rate of structure build up was dependent on the concentration of hydrogel.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725554.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hydrogels; 0 / microcrystalline cellulose; 9004-32-4 / Carboxymethylcellulose Sodium; 9004-34-6 / Cellulose
  •  go-up   go-down


81. Rashid M, Ramasamy S, Raghava GP: A simple approach for predicting protein-protein interactions. Curr Protein Pept Sci; 2010 Nov;11(7):589-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We achieved maximum Matthews's correlation coefficient (MCC) of 1.00, 0.52 and 0.74 for Escherichia coli, Saccharomyces cerevisiae, and Helicobacter pylori, using dipeptide based SVM model at default threshold.
  • In case of E. coli MCC decreased from 1.0 to 0.67 when evaluated on a new dataset.
  • We conclude that the primary amino acid sequence based descriptors could be used to differentiate interacting from non-interacting protein pairs.

  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887258.001).
  • [ISSN] 1875-5550
  • [Journal-full-title] Current protein & peptide science
  • [ISO-abbreviation] Curr. Protein Pept. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Dipeptides; 0 / Proteins; 0 / Saccharomyces cerevisiae Proteins
  •  go-up   go-down


82. Morris KL, Williams B, Kennedy GA: Images in haematology. Heavy bone marrow involvement with metastatic Merkel cell tumour in an immunosuppressed renal transplant recipient. Br J Haematol; 2005 Jan;128(2):133
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in haematology. Heavy bone marrow involvement with metastatic Merkel cell tumour in an immunosuppressed renal transplant recipient.
  • [MeSH-major] Bone Marrow Cells / pathology. Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / secondary. Immunocompromised Host. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Chromogranin A. Chromogranins / analysis. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Kidney Transplantation. Male. Polycystic Kidney Diseases / pathology. Polycystic Kidney Diseases / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2005 May;129(3):446 [15842673.001]
  • (PMID = 15638845.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20
  •  go-up   go-down


83. Luo X, Zhang G, Huang F, Rao X, He Y, Hu P: [Study on preparation of Qixian decoction pellets in tangential spray fluid bed]. Zhongguo Zhong Yao Za Zhi; 2009 Mar;34(6):690-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULT: the technological parameters for the preparation of blank pellets were as follows: the ratio of starch and dextrin was 2:1, the adhesive agent was 70% syrup, the rotating speed was 200 r x min(-1), the air blow flow was 15 x 20 L x min(-1), the rate of air flow was 15 L x min(-1), the spay air pressure was 0.15 MPa, and the rotating rate of spray solution pump was 20-50 r x min(-1); The optimized technological parameters for the preparation of Qixian decoction were as follows: the relative density of the extract was 1.12-1.15 g x min(-1), the diluent was MCC and its quantity was 8%, the rotating rate of spray solution pump was 10-12 mL x min(-1), the frequency of the rotor disc was 18-20 Hz, the atomizing pressure was 0.2 MPa, the frequency of the fan was 22 Hz, and the spheronisation and drying time was 30 mins.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624005.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adhesives; 0 / Drug Implants; 0 / Drugs, Chinese Herbal; 0 / qixian
  •  go-up   go-down


84. Muh HC, Tong JC, Tammi MT: AllerHunter: a SVM-pairwise system for assessment of allergenicity and allergic cross-reactivity in proteins. PLoS One; 2009;4(6):e5861
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Testing results showed that AllerHunter, with a sensitivity of 83.4% and specificity of 96.4% (accuracy = 95.3%, area under the receiver operating characteristic curve AROC = 0.928+/-0.004 and Matthew's correlation coefficient MCC = 0.738), performs significantly better than a number of existing methods using an independent dataset of 1443 protein sequences.
  • [MeSH-major] Allergens / chemistry. Computational Biology / methods. Hypersensitivity / diagnosis. Hypersensitivity / genetics

  • MedlinePlus Health Information. consumer health - Allergy.
  • COS Scholar Universe. author profiles.
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 2000 Aug;106(2):228-38 [10932064.001]
  • [Cites] J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38 [9893196.001]
  • [Cites] Int Arch Allergy Immunol. 2002 Aug;128(4):280-91 [12218366.001]
  • [Cites] Brief Bioinform. 2002 Sep;3(3):275-84 [12230036.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):359-62 [12520022.001]
  • [Cites] In Silico Biol. 2002;2(4):525-34 [12611632.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1141-3 [12709401.001]
  • [Cites] Allergy. 2003 Nov;58(11):1083-92 [14616117.001]
  • [Cites] J Comput Biol. 2003;10(6):857-68 [14980014.001]
  • [Cites] Bioinformatics. 2004 Nov 1;20(16):2572-8 [15117757.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D34-8 [15608212.001]
  • [Cites] Bioinformatics. 2005 Jan 1;21(1):39-50 [15319257.001]
  • [Cites] Int Arch Allergy Immunol. 2005 Jun;137(2):153-66 [15947471.001]
  • [Cites] Toxicol Sci. 2006 Mar;90(1):252-8 [16338955.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W202-9 [16844994.001]
  • [Cites] Mol Immunol. 2007 Jan;44(4):514-20 [16563508.001]
  • [Cites] Cell Immunol. 2006 Dec;244(2):90-6 [17467675.001]
  • [Cites] Front Biosci. 2008;13:4882-8 [18508553.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Feb;133(2):101-12 [14739578.001]
  • [Cites] J Allergy Clin Immunol. 2004 May;113(5):805-19; quiz 820 [15131561.001]
  • [Cites] BMC Bioinformatics. 2004 Sep 16;5:133 [15373946.001]
  • [Cites] J Mol Biol. 1981 Mar 25;147(1):195-7 [7265238.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):263-6 [10592242.001]
  • [Cites] Nature. 1993 Dec 2;366(6454):421-8 [8247150.001]
  • [Cites] Methods Enzymol. 1996;266:460-80 [8743700.001]
  • [Cites] Curr Opin Immunol. 1996 Dec;8(6):796-803 [8994858.001]
  • [Cites] Adv Drug Deliv Rev. 2000 Aug 31;42(3):225-38 [10963837.001]
  • (PMID = 19516900.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Allergens
  • [Other-IDs] NLM/ PMC2689655
  •  go-up   go-down


85. Gamblin TC, Finkelstein SD, Upsal N, Kaye JD, Blumberg D: Microdissection-based allelotyping: a novel technique to determine the temporal sequence and biological aggressiveness of colorectal cancer. Am Surg; 2006 May;72(5):445-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdissection-based allelotyping: a novel technique to determine the temporal sequence and biological aggressiveness of colorectal cancer.
  • Pathologic staging in colorectal adenocarcinoma (CA) is based on the concept that the timing of metastatic tumor spread is directly related to the depth of the primary tumor invasion.
  • To evaluate the temporal sequence of CA metastasis, we performed microdissection mutational profiling at multiple microscopic sites of primary and metastatic CA specimens.
  • Primary tumors were microdissected at the deepest point of invasion.
  • Comparative mutational profiling for different genomic loci [1p36(CCM = cutaneous malignant melanoma], 3p26(OGGI = 8 oxoguanine DNA glycosylase), 5q23 (APC, MCC = mutated in colorectal cancer), 9p21(p16/CDKN2A = cyclin-dependent kinase 2A), 10q23(PTEN = phosphatase and tensin homolog [mutated in multiple advanced cancers 11), 12p12(K-ras-2 point mutation), 17p13(TP53), 18q25(DCC= deleted in colorectal cancer) was carried out on each microdissected tissue target using microsatellite loss of heterozygosity determination or DNA sequencing.
  • All primary and metastatic sites of CA manifested acquired mutational change in 18 to 91 per cent of the genomic markers.
  • In 15/21 (71%) cases, metastatic sites lacked a specific allelic loss seen in the corresponding primary tumor, indicating that the metastasis occurred before maximal depth of primary invasion.
  • This was further supported by discordant mutational profiles between primary and secondary tumors, requiring divergent clonal evolution.
  • This is the first report describing the temporal sequence and significance of sequential mutational acquisition in clinical tissue specimens with potential implications for a new molecular pathology approach to classify human cancer.


86. Wallis S, Durham-Hall A, Tandon N, Brotherston TM, Shrestha BM: Merkel cell carcinoma. JNMA J Nepal Med Assoc; 2010 Apr-Jun;49(178):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine tumour of the skin with high rate of local recurrence and distant metastatic potential leading to poor outcomes.
  • Merkel cells are normally found as innervated clusters of cells around hair follicles in the basal layer of the epidermis and are thought to function as touch receptors.
  • Here, we describe a case of MCC in a 71-year-old female and provide an up-to-date review of the literature pertinent to the management of MCC.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21485603.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nepal
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Veness MJ: Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma): an overview on management. Australas J Dermatol; 2006 Aug;47(3):160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma): an overview on management.
  • Merkel cell carcinoma is an uncommon but aggressive primary cutaneous neuroendocrine (small cell) carcinoma.
  • There is ongoing debate regarding the optimal treatment of this disease.
  • The early literature comprised small institutional studies with inherent weaknesses.
  • Despite this, the outcome for patients with unfavourable disease remains poor and in most series 25-30% of patients die as a direct result of Merkel cell carcinoma.
  • The head and neck is the commonest site for presentation (50-60%) and wide excision (2-3 cm) of the primary lesion is usually recommended, although achieving this is often difficult within functional and cosmetic constraints.
  • All clinically node-negative patients should be considered candidates for elective nodal treatment and those with clinical nodal disease should undergo nodal dissection and adjuvant radiotherapy.
  • Recent evidence suggests that patients treated with surgery and adjuvant locoregional radiotherapy experience a better disease-free survival compared with those undergoing surgery alone.
  • The aim of this article is to discuss relevant issues in the management of a patient with Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cutaneous neuroendocrine carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866994.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 50
  •  go-up   go-down


88. Weisser H, Hartschuh W, Greiner A, Bischof M, Enk A, Helmbold P: [Merkel cell carcinoma--clinically often misjudged]. Dtsch Med Wochenschr; 2007 Jul 30;132(30):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma--clinically often misjudged].
  • Merkel cell carcinoma is a rare, rapidly growing, highly malignant dermal tumor which occurs preferentially on light-exposed skin in advanced age.
  • The course of the disease is frequently characterized by the occurrence of lymph node metastases and local recurrences, even in the first year after removal of the primary tumour.
  • The histological pattern is characterized by trabecular strands of small, uniform cells with large basophilic nuclei and typical neuroendocrine granules.
  • The diagnosis is confirmed immunohistochemically by neuroendocrine and epithelial markers.
  • The excision of the primary tumor is regarded as first-line therapy.
  • In the stage of nodal disease, a combination of excision and radiotherapy is recommended.
  • Adjuvant chemotherapy can be applied in this stage, as in small-cell bronchial carcinoma.
  • Despite good response to radiatiotherapy and chemotherapy, with at least prolonged recurrence-free intervals, Merkel cell carcinoma is rarely curable at the distant metastasizing stage.
  • Individually defined, aggressive treatment,including radiatiotherapy, may in future considerably improve the prognosis, especially in the early stages of the disease.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Carcinoma, Merkel Cell / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628844.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


89. Weeraratna AT, Houben R, O'Connell MP, Becker JC: Lack of Wnt5A expression in Merkel cell carcinoma. Arch Dermatol; 2010 Jan;146(1):88-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of Wnt5A expression in Merkel cell carcinoma.
  • [MeSH-major] Carcinoma, Merkel Cell / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics. Wnt Proteins / genetics
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Immunohistochemistry. Polymerase Chain Reaction. Wnt-5a Protein

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083703.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 AI999999; United States / Intramural NIH HHS / /
  • [Publication-type] Letter; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt-5a Protein
  •  go-up   go-down


90. Heath ML, Nghiem P: Merkel cell carcinoma: if no breslow, then what? J Surg Oncol; 2007 Jun 15;95(8):614-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: if no breslow, then what?
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Surg Oncol. 2007 Jun 15;95(8):618-22 [17345617.001]
  • (PMID = 17221860.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


91. Gao LB, Kan J, Fan Y, Zhang LY, Liu SH, Chen ZN: Wirelike dinuclear ruthenium complexes connected by bis(ethynyl)oligothiophene. Inorg Chem; 2007 Jul 9;46(14):5651-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Successive increase of thiophene spacers in mixed-valence complexes {RuII}-CC(C4H2S)mCC-{RuIII} (m=1, 2, 3) induced a smooth transition from almost electronic delocalization (m=1) to localization (m=3).
  • For binuclear ruthenium complexes with intramolecular electron transfer transmitted across nine Ru-C and C-C bonds, electronic conveying capability follows {Ru}-CC(CC)2CC-{Ru}>{Ru}-CC(C4H2S)CC-{Ru}>{Ru}-CC(C6H4)CC-{Ru}>{Ru}-CC(CH=CH)2CC-{Ru}.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511449.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Toskala E, Rautiainen M: Effects of surgery on the function of maxillary sinus mucosa. Eur Arch Otorhinolaryngol; 2005 Mar;262(3):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the mucociliary clearance (MCC) in maxillary sinuses in chronic sinusitis before ESS and 6 months after the operations.
  • The correlation of histology to MCC was also studied.
  • Measurements of the mean residual mucociliary clearance (MCC) of maxillary sinuses was studied pre- and postoperatively with an isotope method.
  • Preoperative residual MCC from the maxillary sinuses was 77+/-26% (mean+/-SD).
  • Six months postoperatively, residual MCC was 70+/-22%, only slightly better than preoperatively.
  • Residual MCC was considered good (< or = 50%) in 12% of sinuses preoperatively and in 20% postoperatively.
  • As a single EM finding, metaplasia gave the poorest MCC (91%) and microvilli the best (68%).
  • MCC correlates well with the histology of the mucosa.
  • [MeSH-minor] Biopsy. Chronic Disease. Humans. Mucociliary Clearance / physiology. Time Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otolaryngol. 2003 Oct;123(8):954-9 [14606599.001]
  • [Cites] Laryngoscope. 1998 Mar;108(3):426-30 [9504619.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):315-27 [11786425.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Jun;102(6):459-66 [8512274.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):645-7 [8499095.001]
  • [Cites] Laryngoscope. 1987 Aug;97(8 Pt 3 Suppl 43):1-9 [3613804.001]
  • [Cites] Am Rev Respir Dis. 1974 Sep;110(3):301-5 [4472209.001]
  • [Cites] Rhinology. 2000 Sep;38(3):120-3 [11072657.001]
  • [Cites] Arch Otolaryngol. 1985 Sep;111(9):576-82 [4026673.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1994;251(2):76-9 [8024765.001]
  • [Cites] Rhinology. 1994 Dec;32(4):161-5 [7701222.001]
  • [Cites] J Allergy Clin Immunol. 1997 Jan;99(1 Pt 1):48-52 [9003210.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 May;104(5):350-7 [7747904.001]
  • [Cites] Am J Rhinol. 1998 Jan-Feb;12(1):53-8 [9513660.001]
  • [Cites] Rhinology. 1988 Dec;26(4):257-62 [3238281.001]
  • [Cites] Rhinology. 1994 Sep;32(3):137-40 [7839085.001]
  • [Cites] Arch Otolaryngol. 1982 Feb;108(2):99-101 [6460494.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Feb;94(2):143-7 [3083326.001]
  • [Cites] Acta Otolaryngol. 2001 Jan;121(1):5-9 [11270494.001]
  • [Cites] Acta Otolaryngol. 1995 Jan;115(1):61-5 [7762387.001]
  • (PMID = 15133685.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Kaygusuz G, Kuzu I: Friend leukemia virus integration-1 (FLI-1) expression in gastrointestinal stromal tumors. Turk J Gastroenterol; 2009 Jun;20(2):83-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukemia virus integration-1 (FLI-1) expression in gastrointestinal stromal tumors.
  • BACKGROUND/AIMS: Friend leukemia virus integration-1 expression has been shown in a variety of tumors, including vascular tumors, desmoplastic small round cell tumor, Merkel cell carcinoma, and lymphoblastic lymphoma, in addition to Ewing's sarcoma/primitive neuroectodermal tumor.
  • The aim of the current study was to examine Friend leukemia virus integration-1 protein expression in a series of gastrointestinal stromal tumors and also to assess if Friend leukemia virus integration-1 has any role in the disease process.
  • It is the first study analyzing Friend leukemia virus integration-1 expression in gastrointestinal stromal tumors in the English literature.
  • METHODS: A tissue microarray block containing 52 cases of gastrointestinal stromal tumors was done.
  • CONCLUSIONS: Friend leukemia virus integration-1 can be expressed in a variety of tumors, and is helpful in making the diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor.
  • We think that this protein is not expressed in gastrointestinal stromal tumors and it is not a part of the pathogenesis of this disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / metabolism. Gene Expression. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530039.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FLI1 protein, human; 0 / Proto-Oncogene Protein c-fli-1
  •  go-up   go-down


94. Piérard-Franchimont C, Devillers C, Piérard GE: [Merkel cell carcinoma: from diagnosis to therapeutic management]. Rev Med Liege; 2009 Oct;64(10):500-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma: from diagnosis to therapeutic management].
  • [Transliterated title] Le carcinome de Merkel: du diagnostic à la prise en charge thérapeutique.
  • Merkel cell carcinoma is a skin malignancy showing an increasing trend of incidence in the white population.
  • The diagnosis relies on the histological and targeted immunopathological examinations.
  • An assessment using medical imaging is important to establish.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911663.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


95. Jabbour J, Cumming R, Scolyer RA, Hruby G, Thompson JF, Lee S: Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Ann Surg Oncol; 2007 Jun;14(6):1943-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004.
  • BACKGROUND: Wide surgical excision, lymph node dissection, and radiotherapy have been used with varying efficacy in the management of early-stage Merkel cell carcinoma.
  • METHODS: Records of 82 patients with early-stage Merkel cell carcinoma between 1992 and 2004 were reviewed.
  • Twenty-nine patients presented with regional lymph node disease, which was independently associated with diminished survival (hazard ratio [HR], 4.08; 95% confidence interval [CI], 1.55-10.75; P = .005).
  • Lymphadenectomy was independently associated with prolonged disease-free survival (median, 28.5 vs. 11.8 months; HR, .46; 95% CI, .22-.94; P = .034) but not overall survival (P = .25).
  • Margin-negative excision of the primary tumor (60 of 73) was not significantly associated with either prolonged disease-free survival (median, 16 vs. 14 months) or overall survival (median, 54 vs. 34 months).
  • Forty-eight patients received radiotherapy: 36 to the primary site and 31 to the regional lymph nodes.
  • Radiotherapy to both sites was associated with a longer median time to first recurrence (primary site, 24.2 vs. 11.8 months; regional lymph nodes, 46.2 vs. 11.3 months) and survival (primary site, 53.9 vs. 45.7 months; regional lymph nodes, 103.1 vs. 34.2 months).
  • CONCLUSIONS: Adjuvant radiotherapy to the primary site after surgical excision is recommended in early-stage disease.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Lymph Node Excision. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / radiation effects. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356954.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Gröger A, Piatkowski A, Unglaub F, Bozkurt A, Pallua N: [Merkel cell carcinoma and immunosuppression: report of three cases and review of therapeutic options]. Handchir Mikrochir Plast Chir; 2008 Apr;40(2):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma and immunosuppression: report of three cases and review of therapeutic options].
  • [Transliterated title] Das Merkel-Zell-Karzinom und immunsuppression: drei fallberichte und uberblick der therapeutischen optionen.
  • Merkel cell carcinoma (MCC) is a cutaneous, neuroendocrine tumour of high malignancy that is described as a firm, purple tumour localised in the dermal layer.
  • The course of disease is characterised by high relapse rate (30 - 77 %) and lymph node metastases (ca. 50 %).
  • Therapy of MCC is based on a radical surgical excision combined with sentinel lymph node biopsy (stadium I), lymph node dissection (stadium II) and postoperative radiotherapy.
  • We report three cases of MCC under immunosuppression and present therapeutic options of MCC in overview.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Immunocompromised Host. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Arm. Cheek. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Surgical Flaps. Thigh. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437669.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K: Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Mapp; 2009 Aug;30(8):2336-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It encompasses the anterior cingulate, midcingulate, posterior cingulate, and retrosplenial cortices (ACC, MCC, PCC, and RSC, respectively).
  • The hierarchical clustering analysis distinguished ACC, MCC, PCC, and RSC as independent regions.
  • The MCC has lowest AMPA, kainate, alpha(2), and D(1) densities.
  • Area 25 in ACC is similar in receptor-architecture to MCC, particularly the NMDA, GABA(A), GABA(B), and M(2) receptors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19034899.001).
  • [ISSN] 1097-0193
  • [Journal-full-title] Human brain mapping
  • [ISO-abbreviation] Hum Brain Mapp
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS44222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Adrenergic; 0 / Receptors, Cholinergic; 0 / Receptors, Dopamine D1; 0 / Receptors, GABA; 0 / Receptors, Glutamate; 0 / Receptors, Serotonin
  •  go-up   go-down


98. Duncavage EJ, Zehnbauer BA, Pfeifer JD: Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol; 2009 Apr;22(4):516-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma.
  • It has recently been shown that Merkel cell carcinoma, a rare and often lethal cutaneous malignancy, frequently harbors a novel clonally integrated polyomavirus aptly named Merkel cell polyomavirus.
  • We aimed to study the prevalence of Merkel cell polyomavirus in cases of Merkel cell carcinoma, using specimens from formalin-fixed, paraffin-embedded tissue blocks.
  • In our archives we identified 41 cases of Merkel cell carcinoma (from 29 different patients).
  • Of these, 20 cases were primary cutaneous tumors, 4 were local recurrences, and 17 were metastases.
  • The detection rate of Merkel cell polyomavirus for each of the three primer sets was 22 of 29 patients (76%) for MCVPS1, 12 of 29 (41%) for LT3, and 8 of 29 (28%) for LT1.
  • Our findings provide further evidence to link Merkel cell polyomavirus with a possible role in the oncogenesis of Merkel cell carcinoma.
  • On a more practical level, our paraffin-optimized primer set may be used as an ancillary test to confirm the diagnosis of Merkel cell carcinoma in the clinical setting or for screening other rare tumor types for the causative virus, especially those tumor types that are underrepresented in frozen tissue repositories.
  • [MeSH-major] Carcinoma, Merkel Cell / virology. Polyomavirus. Polyomavirus Infections / epidemiology. Skin Neoplasms / virology. Tumor Virus Infections / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252474.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


99. Javadzadeh Y, Shariati H, Movahhed-Danesh E, Nokhodchi A: Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev Ind Pharm; 2009 Feb;35(2):243-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation of effects of different grades of microcrystalline cellulose (MCC) on flowability, compressibility, and dissolution of liquisolid systems were the aims of this study.
  • For this means, several formulations were prepared using various grades of MCC as carrier.
  • The results showed that among the evaluated different grades of MCC, compacts containing MCC PH 101 and 102 showed better dissolution profiles.
  • Harder compacts were obtained using MCC PH 101 and 200 as carriers.
  • Better flowability was observed in compacts containing MCC PH 101.
  • It could be concluded that MCC PH 101 is a suitable carrier for preparing liquisolid systems for having acceptable flowability, friability, hardness, and dissolution profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785038.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Excipients; 0 / microcrystalline cellulose; 13T4O6VMAM / Piroxicam; 9004-34-6 / Cellulose
  •  go-up   go-down


100. Deganello A, Manciocco V, Dolivet G, Leemans CR, Spriano G: Infrahyoid fascio-myocutaneous flap as an alternative to free radial forearm flap in head and neck reconstruction. Head Neck; 2007 Mar;29(3):285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The use of microvascular free flaps is currently the favored method for the reconstruction of defects after resection of head and neck cancer.
  • METHODS: We reviewed a series of 13 patients with defects resulting from cancer of the head and neck, who underwent infrahyoid flap reconstruction as an alternative to free radial forearm flap.
  • The series includes 12 squamous cell carcinomas arising from the oral cavity and oropharynx, and 1 Merkel cell carcinoma of the submental skin.
  • CONCLUSIONS: The IHFMCF is a versatile, reliable, and convenient flap suitable for repairing small and medium-sized defects of the oral cavity and oropharynx and obviates the need for a microvascular reconstruction.
  • [MeSH-major] Carcinoma, Merkel Cell / surgery. Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Laryngectomy. Male. Middle Aged. Neck Dissection. Necrosis. Pharyngectomy. Reconstructive Surgical Procedures. Retrospective Studies






Advertisement